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Abstract 
 
 
  
MECHANISMS OF ANTIBODY-MEDIATED PROTECTION FOR A 
PROTEIN BASED SMALLPOX VACCINE 
 
MATTHEW E. COHEN 
STUART N. ISAACS 
 
Protein-based smallpox vaccines have shown to be effective alternatives to live virus 
vaccines in animal model challenge studies. It is believed that subunit vaccine protection is 
mainly mediated through the generation of antibodies. We, and others, have shown that Th1-
type antibody responses are important for protection against poxvirus infections. This finding 
suggests that antibody-mediated protection by a protein-based smallpox vaccine may involve 
antibody that can fix complement and/or activate Fc receptors. Vaccinia virus, the prototype 
member of the poxvirus family, produces two infectious forms of virus: mature virus (MV) 
and extracellular virus (EV). EV is relatively resistant to neutralization by antibody, yet 
antibody against EV has been shown to protective in vivo. Therefore, we examined the 
importance of complement and Fc receptors in the protection afforded by antibody against 
EV. In the first part of this thesis, we found that polyclonal antibody against the EV proteins 
A33 and B5 can fix complement to efficiently neutralize EV in vitro. Additionally, we found 
that the complement activation requirements necessary for neutralization differ depending on 
the EV protein target used. We attribute these differences to the amount of A33 and B5 
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protein found on the EV outer membrane. We then show that in mice, both complement and 
Fc receptors are important for protection mediated by polyclonal antibody against the EV 
protein B5. In the last section, we found that non-human primates are better protected from 
monkeypox virus challenge by protein vaccination when the vaccine formulation generates 
more Th1-like antibody responses. Individual non-human primates receiving this vaccine had 
more homogeneous antibody responses that could neutralize EV in the presence of 
complement. Together, these studies implicate an important role for complement and Fc 
receptors in the protection by antibody against the EV form of poxviruses. This work 
highlights the importance of analyzing the mechanisms by which antibody provides 
protection from viral infection so that antibody-based vaccines and therapeutics can be more 
efficiently designed. 
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Chapter One: Poxviruses and the Contribution of Antibody to Protection In Vitro 
and In Vivo 
 
Introduction, Part I 
 
Matthew E. Cohen and Stuart N. Isaacs 
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I. Introduction 
 Poxviruses are large, double-stranded DNA viruses. They include many species 
that infect humans and can cause disease such as monkeypox virus (MPXV), cowpox 
virus (CPXV), and variola virus (VARV), the highly transmissible causative agent of 
smallpox. Smallpox plagued humankind for thousands of years with the earliest evidence 
of telltale pockmark disease found on the mummified remains of ancient Egyptian 
Pharaoh Ramses V, who died in 1157 B.C. (1). Fatality rates from smallpox infections 
can reach 50% in the unvaccinated (2); therefore, it’s no surprise that billions suffered 
from this terrible disease (3). In addition to smallpox, both MPXV and CPXV are 
zoonotic infections that can be transmitted to humans from their rodent reservoirs. Most 
human MPXV infections occur in Central and West Africa and have mortality rates 
between 1-15% (4,5). In 2003, a MPXV outbreak in the Midwestern United States 
highlighted the need to monitor this virus as a potential deadly emerging human pathogen 
(6). CPXV was the source of the original smallpox vaccine used by Edward Jenner in 
1796 (3) and is currently endemic in Western Europe (7). Although disease is typically 
mild, severe and deadly infections can occur in people who are immunocompromised or 
atopic (8).  
Fortunately, VARV was declared eradicated in 1980, thanks in large part to heroic 
effort by the World Health Organization, and vaccination with an antigenically cross-
reactive virus called vaccinia virus (VACV). Inoculation with live VACV in the skin 
greatly reduces incidence of morbidity and mortality and severs the transmission chain of 
the virus. After eradication of smallpox was declared, vaccination rates greatly declined 
given the potential serious adverse events from live VACV infection. Historical data 
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suggests death occurs in approximately one in a million people that receive the live virus 
vaccine (9,10) though that may be higher now with recent increases in the numbers of 
immunocompromised individuals due to HIV/AIDS, cancer, and transplantation (11). 
Additionally, a rise in the numbers of those with atopic dermatitis and other underlying 
skin conditions increases the potential for serious adverse events following vaccination.  
Vaccination with live VACV can result in four major types of serious 
complications (12,13). Eczema vaccinatum can occur in those suffering from or with 
history of eczema. Skin eruptions occur at sites of the body that were at that time or 
previously had been affected by eczema with eruptions sometimes spreading to healthy 
skin. Symptoms are severe with the outcome largely dependent on the amount of skin 
affected. Progressive vaccinia or vaccinia necrosum occurs in those suffering from 
immunodeficiency. In these cases, the primary vaccination site fails to heal and 
secondary lesions are found on other parts of the body. The infection continues to spread 
with a high rate of mortality occurring 2 to 5 months after vaccination. Another serious 
complication is postvaccinial encephalitis, which occurs in two main forms. The first 
occurs most often in infants less than two years old and has a violent onset, characterized 
by convulsions. Even after recovery, many patients are left with cerebral impairment and 
paralysis. The second form occurs most often in children older than two years and has an 
abrupt onset, with fever, vomiting, headache, and malaise, followed by loss of 
consciousness, amnesia, confusion, restlessness, convulsions and coma. The fatality rate 
is high with death occurring within a week. A fourth, recently rediscovered complication 
is myopericarditis (14,15). Recent smallpox vaccination programs have found an 
association between vaccination and patients experiencing chest pain, shortness of breath, 
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and heart attack. Currently, vaccination with live VACV is contraindicated in the 
following populations: pregnant women, those with immune disorders or therapeutically 
induced immunosuppression, those with HIV infection, those with a history of eczema, 
infants under 12 months of age, and those with heart disease. 
Fortunately, routine smallpox vaccination is no longer needed, as VARV is not 
endemic in any part of the world. Presently, VARV stocks are kept under close guard at 
the CDC in Atlanta and in Russia at the State Research Center of Virology and 
Biotechnology, known as Vector. However, the Soviet Union had developed VARV as a 
bioweapon and after the collapse of the Soviet Union, it was unknown whether these 
stocks were properly destroyed and/or accounted for. Because of this, some speculate that 
VARV could be used as a biological weapon by terrorists or a rogue nation state (16). In 
addition, recent technical advances that could allow whole genome synthesis (17-19) has 
sparked concern that an intentional or unintentional release of VARV could occur and 
spark an outbreak of smallpox in the rapidly growing unvaccinated population. Also, the 
fear that MPXV could evolve to transmit from human to human more efficiently and 
have increased virulence has lead to the stockpiling of smallpox vaccine in the United 
States and other developed countries around the world (20-22). 
Given the serious risks associated with vaccination, a large effort has been made 
to invent and develop new, safer smallpox vaccines (23). These include attenuated strains 
of VACV as well as subunit DNA and protein vaccines and are discussed further in 
chapter two of this thesis. Protein vaccination is an attractive, safe option as it relies on 
the delivery of a small number of proteins and adjuvant to induce a protective antibody 
immune response. The work presented here examines both in vitro and in vivo the 
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mechanisms through which this antibody response can provide protection and highlights 
the importance of evaluating the immune requirements for protection from disease to aid 
in the rational design of new vaccines and therapeutics. 
 
II. Virus structure and lifecycle 
A. Virus structure 
Infection with poxviruses results in the formation of two, morphologically distinct 
infectious forms: mature virus (MV) and extracellular virus (EV) (24). The MV form is 
the predominant form of virus produced during infection. MV is released in large number 
from killed infected cells, is environmentally stable, and thought to be responsible for 
host-to-host transmission. MV particles have a brick-shaped morphology and contain 
over 20 viral proteins in their lipid envelope. Some of these surface proteins are 
responsible for attachment to cells via cell surface proteoglycans (25-29). Other viral 
envelope proteins on MV are part of the indispensable multi-protein entry fusion complex 
(EFC) and mediate fusion of the virus with cellular lipid membranes (30,31). Protein L1 
is found on the surface of MV and is an essential attachment and entry factor, though not 
directly part of the EFC (32). Within the MV envelope is a dense protein core that 
contains a double-stranded DNA genome and other proteins that initiate infection upon 
entry into the cell (33).  
EV particles are MV wrapped with an additional lipid membrane containing six 
viral proteins and are released from infected cells using an active process (34-36). The six 
viral proteins found on the outer membrane of EV are A33, A34, A56, B5, F13, and F12. 
Of these, only A33, A34, A56, and B5 are exposed on the surface of EV and therefore are 
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potential targets of a neutralizing antibody immune response. Because none of these 
proteins are capable of fusing with cells, this presents a unique morphological problem 
for EV to enter cells. To solve this, the B5 protein is capable of interacting with cell 
surface proteoglycans to trigger the non-fusogenic dissolution of the outer membrane of 
EV, thereby exposing the EFC of MV and allowing entry (37,38).  
EV is responsible for dissemination of virus within an infected host. Indeed, the 
deletion of viral proteins responsible for formation of EV leads to highly attenuated 
viruses that spread poorly in vivo (39-43). The outer lipid membrane of EV provides a 
number of unique biological advantages that allow successful spread within a host. 
Compared to MV, EV particles are relatively resistant to antibody neutralization (44,45). 
The EV particle is also relatively resistant to complement as it contains a number of host-
cell derived complement regulatory proteins that down-modulate the deposition of 
complement proteins on the virus as well as preventing the lysis of viral particles (46). 
The small number of viral proteins on EV also makes it less likely to be detected by the 
host immune response.  
Poxviruses have large genomes, consisting of ~200 kb of covalently-closed linear 
double-stranded DNA that encodes for >200 proteins (33). Genes responsible for 
replication and assembly of viral particles are highly conserved, while immune 
modulatory and host-range proteins are much less well conserved and give diversity to 
different poxvirus species (47). Notably, it’s believed that pathogenesis in each specific 
host for each poxvirus species can at least be partially attributed to the adaptation of these 
variable proteins. Many of the proteins that are targeted by the antibody response to 
infection are partially conserved throughout the poxviruses, though can contain some 
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amino acid differences from species to species (48,49). This genetic similarity allows for 
cross-species protection and for VACV vaccination to protect against the related VARV 
and MPXV. 
 
B. Virus lifecycle 
 The poxvirus lifecycle is depicted in Fig. 1-1 (modified from (50) and reprinted 
with permission). Poxviruses first bind to cell surface glycosaminoglycans (GAGs), 
which can increase the efficiency of cell penetration (29). The mechanism for entry of 
poxviruses into cells can occur via two different pathways: Fusion at the plasma 
membrane (29,51,52) or apoptotic mimicry and the hijacking of macropinisomes 
followed by low-pH induced fusion within the macropinosome (51,53-56). The cellular 
receptor(s) that triggers entry/fusion is unknown, as is the mechanism by which the EFC 
is used to fuse the viral and cellular membranes to deliver the viral core into the 
cytoplasm. After fusion of the MV membrane with the cellular membrane, the viral core 
is transported along microtubules to a perinuclear location in the cell (57). As the core 
begins to uncoat, early gene expression begins to occur as the virus starts to prepare the 
cell environment for optimal conditions to replicate and create more viral particles. At 
this time, the virus begins to create a “virus factory” adjacent to the nucleus where the 
ultimate assembly of new virus will take place (58). The “factory” is surrounded by 
membrane, likely derived from the endoplasmic reticulum (59), and it is where all viral 
transcription, translation, and DNA replication take place. Confining the space within 
which these processes occur likely enhances the efficiency of poxvirus replication and 
facilitates competition for cellular resources.  
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Figure 1-1. The poxvirus lifecycle. 
Poxviruses have two infectious forms that are capable of infecting cells, the mature virus 
(MV) and extracellular virus (EV). After entry (1), the core begins to uncoat and early 
transcription/translation begins (2). DNA replication and virion assembly occur in the 
perinuclear viral factory (3 and 4). MV is the predominant form assembled; however, 
some of the MV is targeted to the trans-Golgi network (5) where it is wrapped with two 
additional membranes to become intracellular enveloped virions (IEV) (6). The outer 
membrane of IEV fuses with the plasma membrane leaving the EV form of the virus 
attached to the infected cell surface. EV can then polymerize actin to propel the virus 
away from the infected cell (7) or be released from the cell through an active cell 
signaling process. Modified figure reprinted from (50) with permission. 
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 Poxvirus gene expression is temporally regulated (60) and is divided into three 
main categories: early, intermediate, and late. Early gene expression provides the virus a 
suitable environment to replicate and is required for succession to DNA replication, 
intermediate gene expression, and late gene expression (33). Early genes include proteins 
that shut off the host defense response which attempt to abort viral replication (61). 
Following early gene expression, DNA replication occurs and is a required precursor to 
intermediate and late gene expression (62,63). If DNA replication is prevented, late gene 
expression cannot occur. As DNA replication occurs, the transcription of intermediate 
genes begins. Intermediate gene products are few in number and mostly serve as 
transcription factors that turn on late gene expression (62,64,65). Lastly, late gene 
expression occurs and provides the proteins necessary for assembly of new virions (33), 
as well as proteins that are incorporated into new virions to allow early gene expression 
to occur in the next round of infected cells (66).  
 Viral assembly within the “virus factory” is a complicated process that includes 
non-infectious intermediate-step viral particles. Assembly starts with the formation of 
protein scaffolded membrane crescents (67,68) that mature into complete protein shells 
called immature virions (IV). Next, viral genomes and proteins required for early gene 
transcription are packaged into IV (69). Cleavage of core proteins occurs creating MV 
that leaves the factory (70,71). While this is the predominant form of virus produced, a 
small subset of MV leave the factory and acquire two additional membranes from the 
trans-Golgi network (TGN) or endosomes (72,73). These viral particles are known as 
intracellular enveloped virions (IEV) and contain a distinct subset of viral proteins, 
including those found on the EV particle (33). During infection the EV unique proteins 
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are targeted to the TGN and endosomes, as well as the cell surface. After wrapping, the 
IEV are transported to the perimeter of the cell on microtubules (74-76). When the 
plasma membrane of the cell is reached and the cortical layer of actin breached (77), the 
outer membrane of IEV fuses with the cellular plasma membrane leaving a double 
membrane cell-associated extracellular virus (CEV) particle attached to the cell surface 
(78). The CEV can infect an adjacent cell or can be pushed away from the cell it is 
attached to toward uninfected cells by activating actin filament polymerization 
underneath it in a Src-kinase dependent manner (79-81). Additionally, the CEV can be 
released from the cell in an active, Abl-kinase dependent manner to form EV (35). The 
release of CEV to EV is important for full virulence during a poxvirus infection as 
evidenced by a reduction in virulence in vivo by an Abl-kinase inhibitor drug that blocks 
release of EV from the host-cell surface (35). 
 
III. Poxvirus Immunity 
A. Protective immune responses from primary infection 
 The first line of host defense against poxvirus infection is the innate immune 
response. This response is important for controlling virus replication early during 
infection and allows sufficient time for, as well as helps activate, an adaptive immune 
response. Evidence for the importance of innate immunity during poxvirus infections is 
found in the numerous innate immune response modifier proteins encoded by poxvirus 
genomes (61). These poxvirus virulence proteins target key innate pathways including 
interferons, chemokines, complement, and the toll-like receptor (TLR) family of pattern 
recognition receptors.  
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 The ectromelia virus (ECTV) model system has been frequently used to examine 
immune requirements for protection from primary infection in mice because it is a highly 
lethal, species-specific poxvirus infection similar to VARV in humans. The IFNα/β 
binding protein from ECTV has been found to be critical for virulence indicating that 
IFNs are important in mounting a host response against ECTV (82). Many poxviruses 
encode numerous chemokine-binding proteins that could act to modify the recruitment of 
cellular responses to infection. Indeed, NK cells have been shown to be critical for 
control of ECTV following challenge of ECTV resistant strains of mice (83-85). Also, 
mice lacking complement have been found to be more susceptible to a primary ECTV 
infection (86). TLR9 signaling to activate dendritic cells is critical in survival from a 
lethal ECTV infection in mice (87). While innate immune responses are important and 
help shape adaptive immune responses to infection, they are not sufficient to control and 
clear poxvirus infections.  
 In addition to innate immunity, adaptive immunity is also required to control and 
clear infection of poxviruses. Studies with ECTV infection in mice have shown that both 
B cell and T cell responses are critical for controlling a primary infection and ultimately 
protecting mice from lethal disease. B cell deficient mice (µMT-/-), despite mounting 
robust CD8+ T cells responses, succumb to ECTV infection within 3 weeks post 
infection (88). A similar study found that mice that are incapable of mounting antibody 
responses (µMT-/-; MHCII-/-; or CD40-/-) are able to survive infection for greater than 1 
month, but ultimately are unable to clear the virus and succumb to infection (89). T cell 
responses are also critical for clearing a primary ECTV challenge. The depletion of CD8+ 
T-cells from mice normally resistant to ECTV makes them highly susceptible to ECTV 
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and these mice succumb to infection by day 8 (88,89). Together, these studies illustrate 
that CD8+ T-cells, CD4+ T-cells, and antibody are critical in controlling primary ECTV 
in mice. These findings with ECTV also suggest that for a highly lethal, species-specific 
poxvirus infection, T-cells are required to control infection early and limit replication at 
the site of infection, while antibody is critical to clear the virus and prevent dissemination 
within the host. 
 
B. Vaccination induced protective immune responses 
The smallpox vaccine induces strong, long-lived adaptive immune responses. In 
humans, vaccinia-specific antibody levels and neutralizing titers have been shown to 
persist for decades and vaccinia-specific memory B-cell responses are functional and 
maintained for more than 50 years (90-92). CD4+ and CD8+ T-cell responses peak at 2-4 
weeks post vaccination and contract to form a stable pool of memory T-cells that can last 
for decades (92,93).  
While smallpox vaccine generates a fully protective immune response, the 
specific correlates of protection in humans are unknown. In order to develop new, safer 
vaccines against smallpox, researchers have turned to animal models to study the ability 
of antibody and T-cells to provide protection together or on their own. Passive 
immunization with anti-vaccinia sera or anti-vaccinia primed CD8+ T-cells in mice has 
been shown to be sufficient on their own to provide protection from VACV or ECTV 
challenge (89,94-101). Mice vaccinated with VACV and then depleted of CD8+ or CD4+ 
T cells were fully protected from challenge (100). Vaccinated mice depleted of B-cells 
prior to VACV challenge lost some protection normally seen in wild-type mice, though 
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mice still survived VACV challenge indicating that T-cells may be sufficient to prevent 
death (100). If these mice were depleted of both B-cells and T-cells, mice succumbed to 
infection. In a separate study, vaccinia-specific memory CD8+ T cells were transferred 
into naïve mice and had the ability to protect in the absence of other preexisting adaptive 
immunity (102).  
While these results suggest a role for CD8+ T-cells in protection after 
vaccination, using the ECTV and MPXV models reveals an even greater dependence on 
antibody for protection after live virus vaccination. Mice vaccinated with an avirulent 
strain of ECTV and subsequently depleted of CD8+, CD4+, or CD8+/CD4+ T-cells are 
protected from a lethal ECTV challenge (103). The engagement of B-cells and the 
production of an antibody response are critical for protection after vaccination with an 
avirulent ECTV. Mice lacking B-cells (µMT-/-) or the ability to mount an antibody 
response (MHCII-/- or CD40-/-) vaccinated with avirulent ECTV remained susceptible to 
ECTV infection and had similar times to death as naïve mice (103). All protection 
correlated with the production of an antibody response and effective virus control. 
In a model of MPXV challenge, nonhuman primates (NHPs) are protected from 
lethal infection if they are first vaccinated with VACV (104-106). Depletion of CD8+ or 
CD4+ T cells at the time of challenge had no effect on this protection and NHPs were 
free from signs of disease (107). However, depletion of B-cells at the time of challenge 
abrogated protection and led to the death of 3 of 4 NHPs with the surviving NHP 
showing signs of morbidity after challenge (107). These MPXV data are in agreement 
with the ECTV data and reflect the requirement for generating an antibody response to 
induce protection against poxviruses. The finding that antibody is necessary and 
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sufficient for protection against challenge with lethal, systemic infection suggests that 
new vaccine strategies that focus on inducing an antibody response can be sufficient for 
protection. Indeed, subunit protein vaccination that induces primarily a strong antibody 
response has been promising in mouse and NHP models of infection (98,105,108-110). 
These vaccines are discussed in greater detail in chapter two. 
 
IV. Antibody Neutralization of Poxviruses 
A. Overview 
 Antibody neutralization of poxvirus plays a critical role in protection from 
disease. Many studies have used VACV as a model to ascertain the protein targets of 
neutralization. Both the MV and EV forms of the virus are targets of the neutralizing 
antibody response (44,111-116). While MV is much more sensitive to antibody 
neutralization, EV neutralization can be achieved with higher concentrations of immune 
serum or purified specific antibody (44,109). Importantly, antibody against MV is 
incapable of neutralizing EV, and vice versa. Not surprisingly, it has been shown that 
inducing or transferring antibody against both forms is more protective than antibody 
against either form alone (96,98). Antibody targeting the MV form is thought to reduce 
the infecting inoculum while antibody that targets EV could alter the spread and 
dissemination of the virus within the host. Therefore, it has been critical to identify 
proteins on both the MV and EV forms that can be targeted by antibody and provide 
protection from challenge. Because poxviruses are so complex and encode for more than 
200 proteins, considerable effort has been made to identify targets of the natural antibody 
response to VACV as well as targets suitable for vaccination.  
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 In addition to targets, the type of antibody response must be considered. 
Vaccination with live VACV induces a potent Th1-biased immune response that 
generates antibody isotypes of IgG2a, IgG2b, and/or IgG2c in mice (105,117,118) or 
IgG1 in non-human primates (Xiao, Isaacs; unpublished results). While direct 
neutralization of virus is dependent on the variable region of the antibody, the ability of 
the Fc region to fix complement can greatly enhance the potency with which an antibody 
can neutralize virus. A number of viruses have been shown to be more easily neutralized 
in the presence of antibody and complement, including West Nile (119), influenza 
(120,121), herpes simplex (122,123), and poxviruses (97,108,124-126). While VACV 
MV is efficiently neutralized by antibody alone, studies have shown that EV is much 
more effectively neutralized by antibody in the presence of complement and protective 
effects in vivo are partially dependent on complement (125). Designing vaccines and 
therapeutic antibodies must take into account not only the antibody targets, but also the 
isotype and Fc functional activity of antibody being generated. 
 
B. Antibody targets 
 The majority of research to identify targets of the antibody response to VACV has 
focused on the surface proteins of MV and EV. Protein targets were identified based on 
the ability of antibody against them to neutralize the virus in vitro or provide protection 
in vivo after passive transfer. Vaccinia Immune Globulin (VIG), a preparation of serum 
from recently vaccinated individuals used to treat vaccine-related complications, has been 
studied to identify what antibodies contained therein are able to neutralize VACV (113-
115,127-129). More recently, a number of labs have used protein microarrays to identify 
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protein targets of the antibody response after vaccination with VACV (114,130-133). 
These studies have shown that the humoral response in humans has a large degree of 
interindividual variability and many different protein targets have antibody generated 
against them. No specific immunodominant targets of the antibody response to MV were 
identified. These studies revealed that antibody is generated against not only surface 
membrane proteins of VACV, but also core proteins and proteins only expressed in 
infected cells. The importance of these responses is currently unknown. The following 
section will discuss the protein targets of neutralizing antibody that have been identified. 
 
Neutralizing targets on mature virus (MV) 
 Neutralization of the MV form of VACV has been the classical standard for 
determining the ability of antibody to provide protection in vivo. MV is typically seen by 
a naïve immune system upon initial infection and this perhaps allows for its enhanced 
sensitivity to neutralization compared to EV (44). To date, the proteins recognized as 
neutralizing targets of antibody on MV are A27, A28, L1, D8, and H3.  
 A27 is a 14 kDa trimeric protein found on the surface of MV and is involved in 
virus attachment to GAGs on cells, virus–cell fusion, and virus release from cells 
(26,134,135). Monoclonal antibody against A27 generated from VACV immunized mice 
neutralizes MV in vitro and protects mice after passive transfer in vivo (136). 
Immunization with smallpox vaccine induces A27 neutralizing antibody, but represents 
only a small fraction of the total neutralizing activity of VIG (128). A27 vaccinations 
with recombinant protein or DNA have had varying degrees of success with providing 
protection from challenge (110,137-139). 
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 A28 is an 18 kDa membrane protein found on the surface of MV and is highly 
conserved between poxvirus species. It was the first identified member of the poxvirus 
EFC (30,140) and has been shown to interact with another protein member of the 
complex called H2 (30,141,142). Vaccination of rabbits with recombinant A28 protein 
induced neutralizing antibody and passive transfer of this antibody protected mice from 
lethal challenge (143). Interestingly, vaccinating mice with A28 and H2 at the same time, 
in the same location, induced a more potent neutralizing antibody response than 
vaccinating mice with A28 alone or A28 and H2 at different sites (144). Because these 
proteins interact on the virus, it is likely that presenting recombinant A28 associated with 
H2 provides a more natural epitope for B-cells to recognize and produces antibody that 
can recognize A28 in its complex form on the virion. This concept is important and likely 
could be extended to a number of poxvirus protein targets. To date, A28 is the only 
member of the EFC that has generated neutralizing antibody, but perhaps the right 
complex of proteins could generate neutralizing responses to other members. 
 L1 is a 29 kDa myristylated protein found on the surface of MV particles and has 
been shown to be involved in virus penetration into cells, though hypothesized to only 
peripherally associate with the EFC (32). Some of the first identified neutralizing 
monoclonal antibodies to VACV were found to target the L1 protein (145-147). Recently, 
it was described that L1 can bind to cells independently of GAGs, suggesting that it may 
be responsible for interacting with an unknown cellular receptor responsible for initiating 
membrane fusion (148). While both A27 and L1 have been studied extensively as targets 
for vaccination, L1 has outperformed A27 and consistently has produced protective 
neutralizing antibody (98,106,108,110,137,149). 
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 D8 is a 32 kDa protein found on the surface of MV and has been shown to bind to 
the GAG chondroitin sulfate and mediate adsorption of MV to cells (28,150). Deletion of 
D8 leads to a reduction in MV titer when growing virus in cell culture (28) and 
replication of a recombinant VACV that has D8 deleted is attenuated in brain tissue 
(151); therefore, blocking interaction of the cell and D8 hampers the ability of poxvirus 
to efficiently enter cells . Antibodies to D8 have been detected in mice immunized with 
VACV (152). Additionally, immunization of mice with D8 in the form of an optimized 
DNA vaccine induced neutralizing antibody (153).  
 H3 is a 35 kDa integral membrane protein of MV and mediates the binding of 
virus to cells through heparin sulfate (154). H3 deleted recombinant virus has a small 
plaque phenotype, though this is partially attributed to defects in morphogenesis. Mice 
passively given rabbit polyclonal anti-sera to H3 are partially protected from challenge 
with VACV (154). Additionally, H3 is a major target of the antibody response to VACV 
vaccination in humans and mice vaccinated with recombinant H3 protein are partially 
protected from challenge (99).  
 
Neutralizing targets on extracellular virus (EV) 
 Compared to MV, EV requires higher concentrations of antibody or serum to 
achieve even modest levels of neutralization in plaque reduction assays 
(44,45,97,108,109,113,125,129,155). Another mechanism by which antibody 
“neutralizes” EV is thought to be through the inhibition of release of EV from infected 
cells (109,110,155). Additionally, recent studies have elucidated a mechanism of 
complement-enhanced antibody neutralization whereby the outer envelope of EV could 
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either be opsonized with complement (125) or lysed by the membrane attack complex 
(MAC) (97). The two identified targets on EV of neutralizing antibody and a protective 
antibody response are A33 and B5. 
 A33 is a 23 kDa type II transmembrane glycoprotein found as a dimer on the 
surface of EV as well as the surface of infected cells both early and late during infection 
(34,156). A33 plays a role in chaperoning A36, a protein important for actin filament 
formation underneath CEV, to the cell surface (157). A33 also plays a role in antibody 
resistant cell-to-cell spread of EV, though the exact mechanism is unknown (158). 
Antibody against A33 is found in the sera of VACV vaccinated humans (112). 
Additionally, a number of studies have shown that passive transfer of A33 antibody is 
protective in vivo, although antibody against A33 does not directly neutralize virions 
(96,109,159). While anti-A33 antibody has not been show to neutralize EV in a plaque 
reduction assay, anti-A33 antibody has been shown to alter “comet-tail” formation in cell 
culture, a phenomenon mediated by the release of EV from infected cells (97,110). This 
prevention of “comet-tail” formation is attributed to the ability of A33 antibody to 
prevent the release of CEV (34). A33 antibody has also been shown to lyse the outer 
membrane of EV in the presence of complement (97). Neutralizing MV antibody was 
then shown to be able to neutralize the MV particle that was released. Finally, A33 
antibody and complement has been reported to be able to lyse infected cells (160), 
indicating that A33 on the infected cell surface can serve as another target of A33 
antibody. While these mechanisms have all been reported in vitro, it’s unclear which ones 
contribute to protection in vivo. Nevertheless, numerous groups have successfully used 
A33 as a vaccination target (98,105,106,108-110,138,149,153,160-162). 
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 B5 is a 42 kDa type I transmembrane glycoprotein and like A33, it is found on the 
surface of EV and on the surface of infected cells both early and late in infection 
(34,163,164). B5 is required for the formation of EV and deletion of B5 leads to a 
reduction in the amount of EV released due to a reduction in the amount of MV that gets 
wrapped in the golgi/endosome (39,165). Because of a reduction in the amount of EV 
released, B5 deleted VACV is attenuated in vivo (39,165). Additionally, B5 is required 
for non-fusogenic dissolution of the outer membrane of EV (37) and deletion of the key 
residues of B5 protein decreases EV infectivity by blocking EV unwrapping to expose 
the EFC on MV (38). Currently, B5 is the only identified target of antibody that can 
directly neutralize EV (44,109) and passive transfer of polyclonal or neutralizing 
monoclonal antibody against B5 can decrease post-challenge morbidity in vivo 
(96,109,124,125,159,166,167). The EV neutralizing activity of VIG is mainly attributed 
to antibody against B5 (113,129). Recently, a monoclonal antibody against B5 was 
shown to neutralize EV, but only in the presence of complement (125). This ability has 
been attributed to the complement fixing IgG2a isotype of this monoclonal antibody and 
protection in vivo was dependent on complement. Unlike A33, opsonization (coating) of 
the EV outer membrane with antibody and complement was shown to be a mechanism 
for complement-mediated neutralization of EV when this B5 monoclonal was used (125). 
Similar to A33, antibody against B5 can lyse infected cells in the presence of 
complement (125). Including B5 as a target of vaccination has been widely successful in 
protecting mice and NHPs from lethal challenge (98,105,106,108-
110,138,149,162,168,169). 
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V. Antibody Effector Mechanisms 
A. Overview 
 Antibodies possess two functional domains: Fab and Fc. The Fab portion of 
antibody is highly variable and allows antibody to recognize and bind widely diverse 
molecular structures. The Fc portion of the antibody is more highly conserved and 
performs two basic functions (170). First, it interacts with the rest of the immune system 
after an antibody has bound its target. This interaction can lead to the activation of a 
variety of effector mechanisms: antibody dependent cellular cytotoxicity (ADCC), 
antibody dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity 
(CDC), and complement-mediated neutralization. ADCC and ADCP are mediated by the 
interaction of the Fc portion with Fc receptors (FcRs) expressed on a variety of immune 
cells including natural killer (NK) cells, macrophages, neutrophils, and monocytes (171). 
CDC and complement-mediated neutralization are mediated by the interaction of the Fc 
with complement component C1 and the resulting activation of the complement system 
(172). The second function of the Fc portion of the antibody is the interaction with the 
neonatal Fc receptor (FcRn) to regulate the half-life of antibody in circulation (170). 
 The classical definition of antibody neutralization has often been defined as the 
interaction between the Fab portion of the antibody and a pathogen target structure such 
that the ability of the pathogen to interact with a cellular receptor or enter cells is 
prevented. However, in vitro non-neutralizing antibodies can actually be neutralizing if 
the assay is performed under conditions that allow Fc domain to function. Antibody 
neutralization can be aided by complement and Fc receptors. After the Fab portion 
recognizes the pathogen, the Fc portion can activate the complement cascade to 
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neutralize the pathogen or it can interact with Fc receptors to form an immune complex 
that can lead to degradation of the pathogen by opsonophagocytosis. For antibody against 
pathogens, the ability to activate these Fc-dependent mechanisms can be crucial for 
protection from disease. Recent studies have encouraged a deeper appreciation for the Fc 
requirements of antibody to provide disease protection from a number of virus pathogens 
including HSV, West Nile, yellow fever, influenza, HIV, and VACV (124,125,173-183).  
 
B. Complement  
The complement cascade 
The complement cascade is part of the innate immune response and is one the earliest 
defense systems to recognize invading pathogens (184,185). Complement is activated by 
three different pathways that use distinct mechanisms to recognize non-self from self: 
classical, lectin, and alternative. The classical pathway is activated by IgM or IgG 
antibody bound to antigen. The C1q complement protein recognizes the Fc portion of the 
bound antibody and initiates the cascade. In mice, IgG2a, IgG2b, and IgG2c are much 
more efficient at activating complement via the classical pathway than IgG1 (186-188) 
and in humans and non-human primates, IgG1 is more efficient at activating complement 
than IgG2 (189,190). The lectin pathway is activated by the mannose-containing 
polysaccharides found on pathogens. The alternative pathway has no specific activator, 
but simply results from low-level cleavage of the C3 protein of complement. If 
complement regulatory proteins are missing from the surface of a pathogen or cell, the 
alternative pathway is amplified in a feedback loop.  
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 All three pathways converge on the formation of a C3 convertase, responsible for 
the continued cleavage of C3 to its active form, C3b, which can bind covalently to nearby 
surfaces. As C3b continues to form, some of it binds back to the C3 convertase to form 
the C5 convertase. The C5 convertase cleaves C5 into C5a and C5b. C5b recruits C6 
through C9 to form the membrane attack complex (MAC), a lytic pore that can lyse 
pathogens and infected cells.  
 
Complement and defense against viral infection 
 Complement is an important first line of defense against virus infections 
(191,192). Complement can opsonize viral particles by the covalent attachment of C3b. 
This can block viral proteins from interacting with the host cell and effectively 
neutralizes the virus. Additionally, viral particles bound with C1q and/or C3b can be 
taken up and degraded by phagocytic cells such as macrophages and neutrophils. The 
formation of the MAC on enveloped viral particles can lyse the membrane and prevent 
the virus from being able to infect the cell. Infected cells that express viral proteins on the 
cell surface can be recognized by antibody and activation of the classical pathway on 
those cells can occur. Formation of the MAC on infected cells is called complement 
dependent cytotoxicity (CDC) and prevents the continued replication of virus in those 
cells. Complement-mediated neutralization and CDC have been shown to be important in 
many viral infections, including influenza, HSV, and poxviruses (125,173,183,193-195). 
In addition to opsonization and the formation of the MAC, complement has been shown 
to enhance adaptive immune responses through its various cleavage products (196).  
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 Because of the anti-viral effects of complement, many viruses have evolved ways 
to evade complement attack. Poxviruses, paramyxoviruses, and several retroviruses 
recruit host regulators of complement and incorporate them into their outer envelope 
(46,197,198). For example, VACV EV is relatively resistant to complement because it 
incorporates the host regulators of complement CD46 (membrane cofactor protein, 
MCP), CD55 (decay accelerating factor, DAF), and CD59 (an inhibitor of MAC 
formation) into its outermost envelope (46). CD46 acts as a cofactor with host regulator 
factor I to degrade C3b into an inactive form effectively preventing the further formation 
of C3 convertases. CD55 is capable of destabilizing the C3 convertase complex, 
rendering it inactive. CD59 can prevent the incorporation of the MAC into membranes 
(199).  
 Poxviruses, HSV, and flaviviruses encode their own proteins that regulate the 
complement cascade (126,183,200-203). Poxviruses encode complement control proteins 
(CCPs) that contain structural homology to host regulators of complement. VACV 
expresses the vaccinia virus complement control protein (VCP) that protects infected 
cells and free virions from complement mediated attack (126,193). HSV and flaviviruses 
encode their own protein regulators of complement, but these contain no structural 
similarity to host regulators of complement. However, both are effective at allowing the 
virus to evade complement and replicate more efficiently (183,201-203).  
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C. Fc receptors 
Overview 
 The Fc portion of antibody engages FcRs after it has bound its antigen (171). In 
the case of ADCC, the result of the three-way interaction between target cell, antibody, 
and an FcR expressing cell (such as an NK cell or macrophage) is cell death. It has long 
been recognized that in the presence of antibody and peripheral lymphocytes, VACV 
infected cells are lysed and killed (ADCC) (204). Additionally, viral pathogens can be 
directly linked to FcR expressing phagocytic cells through antibody and taken up to be 
degraded. Lastly, engagement of FcRs can lead to the expression of cytokines and the 
release of inflammatory mediators, bolstering the immune response in the vicinity of 
bound antibody. 
 
Fc receptor activation 
 There are two main classes of Fc receptors recognized: activation receptors and an 
inhibition receptor (171). Both classes are often found on the same cell and function in 
concert (205). Almost always, co-engagement of these receptors occurs, setting the 
threshold and magnitude of the responses generated. Levels of each type of receptor on 
FcR expressing cells are carefully regulated during the development and differentiation 
of effector cells so that FcR activation receptors are more highly expressed when a strong 
cell-mediated response is needed and FcR inhibition receptors are more highly expressed 
when the response needs to be turned off. In mice, the high-affinity FcγRI, low-affinity 
FcγRIII, and intermediate affinity FcγRIV are activating receptors and share a common 
immune activating tyrosine motif (ITAM) subunit called the γ-chain (171). High-affinity 
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FcγRI can bind monomeric IgG and is found exclusively on macrophages and 
neutrophils. Low-affinity FcγRIII is expressed on NK cells, macrophages, neutrophils, 
and mast cells. The intermediate-affinity FcγRIV was more recently discovered and is 
exclusively expressed on neutrophils, monocytes, macrophages, and dendritic cells (206). 
If the common γ-chain is knocked out, as is the case with FcRKO mice, the activating 
FcRs are still expressed on the cell surface but fail to provide signals to the cells, 
rendering the activation pathways of the FcR system inert. Indeed, activated macrophages 
from FcRKO mice fail to phagocytose antibody-coated beads despite normal binding 
(207). Additionally, NK cells from these mice are defective at performing ADCC (207). 
 The ability of IgG to bind and stimulate activation FcRs is heavily dependent on 
the isotype of the antibody (208). Generally, Th1-type IgG is better at activating Fc 
receptor dependent processes. This is not surprising, as Th1-type cytokines upregulate 
expression of activating FcRs (171). In mice, the high-affinity FcγRI exclusively binds 
IgG2a, while the low-affinity FcγRIII binds IgG1, IgG2a, and IgG2b (171). FcγRIV 
exclusively binds IgG2a and IgG2b with intermediate affinity and does not interact with 
IgG1 or IgG3 antibody isotypes (206). Furthermore, recent findings have suggested that 
immune complexed IgG2a and IgG2b are functionally dependent on FcγRIV, despite 
having an affinity for FcγRI (in the case of IgG2a) and FcγRIII (in the case of IgG2a and 
2b) due to FcγRI being occupied by monomeric IgG2a and FcγRIII having too low an 
affinity to have productive engagement at typical serum levels of antibody (171).  
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Fc receptors and defense against viral infection 
 In support of FcγRIV driving Fc-dependent Th-1 type IgG mechanisms, a 
protective IgG2a West Nile virus monoclonal antibody is rendered ineffective in FcRKO 
mice, but not FcγRIII or NK cell depleted mice, indicating that ADCC by NK cells does 
not mediate protection from West Nile virus infection by IgG2a monoclonal antibody 
(180). Protective antibody to influenza infection has also been shown to be dependent on 
macrophages and not NK cells by an FcR dependent mechanism (178). While NK cells 
and macrophages play a role early during an initial poxvirus infection in a naïve host 
(83,84,209-211), it is less clear what role they might play in a protective Fc-dependent 
antibody mechanisms. Recently, FcRKO mice were shown to be protected from lethal 
ECTV challenge if given a post-exposure immunization with Modified Vaccinia Ankara 
(MVA), an attenuated smallpox vaccine candidate (212). However, in this model, the 
lack of FcRs may be compensated by other immune mechanisms. This thesis begins to 
explore the in vivo role of Fc receptors in protection from VACV challenge in the 
presence of a protective antibody response. 
 
 In the next chapters, we examine the Fc effector mechanism requirements for in 
vitro neutralization of VACV EV with polyclonal antibody responses against the A33 and 
B5 proteins of EV and the Fc effector mechanism requirements for in vivo protection 
from poxvirus challenge after passive and active immunization against B5. 
 
 
 
 28 
Chapter Two: Improved Smallpox Vaccines 
 
Introduction, Part II 
 
Matthew E. Cohen1 and Stuart N. Isaacs1 
 
1Department of Medicine, Division of Infectious Diseases, University of Pennsylvania 
School of Medicine, Philadelphia, PA 19104 
 
This chapter was published in: New Generation Vaccines, 4th edition. Ed. Myron M. 
Levine, Informa Healthcare, 2009.  
Reproduced with permission from Informa Healthcare. 
 
 
 
 
 
 
 
 
 
 
 
 29 
Introduction 
The first preventative vaccines against an infectious agent were orthopoxviruses, 
which were used to prevent smallpox (3). Vaccination with live vaccinia virus resulted in 
cross-protection against infection by variola virus, the causative agent of the deadly 
disease smallpox. Vaccination with vaccinia virus was part of the World Health 
Organization’s (W.H.O.) successful strategy to eradicate smallpox, which made smallpox 
the first, and currently only, disease to be eradicated from plaguing humankind (3). 
However, this success has now led to concern about the accidental or intentional release 
of variola virus (213,214). Because routine vaccination of civilians with vaccinia virus 
vaccines ended with the eradication of smallpox, a large portion of the world population 
is susceptible and for those previously vaccinated, full protection from smallpox may be 
incomplete. In addition to concerns about variola virus, ongoing outbreaks of monkeypox 
in Africa (4,215) and the potential spread of monkeypox to non-endemic areas (6), has 
generated the necessity to have smallpox vaccine available. However, concerns about the 
safety of the smallpox vaccines used in the smallpox eradication program have led to the 
development of new orthopoxvirus vaccines (216-219). 
 
Live vaccinia virus-based vaccines 
Development of a vaccine propagated in cell culture 
The smallpox vaccines that were used around the world to combat smallpox were 
developed in a time well before modern methods of growing and passaging live virus 
vaccines. In the United States, the smallpox vaccine used was Dryvax (manufactured by 
Wyeth Laboratories) and was grown and passaged in the skin of animals. Other parts of 
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the world used other strains of vaccinia virus, and depending upon the strain, different 
rates of vaccine-related severe complications (e.g., death or post-vaccination encephalitis) 
were observed (9). With the eradication of naturally occurring infections from variola 
virus, routine smallpox vaccination ended because the risks (both major and minor) of the 
vaccine were deemed to be too high in the setting of no disease. Without widespread use 
of the vaccine, production ended. While the Centers for Disease Control & Prevention 
(CDC) had access to old stocks of Dryvax, there were not enough doses available to 
combat a large-scale outbreak. Thus, there was great urgency to produce and stockpile 
more vaccine using modern vaccine manufacturing procedures. However, a major 
dilemma was that the virus contained in the Dryvax vaccine represented a swarm of virus 
with unlimited diversity (Russell Regnery, personal communication). A number of 
individual virus plaques from stocks of Dryvax were picked and characterized. The virus 
propagated from a single plaque that most closely resembled the in vitro and in vivo 
characteristics of the Dryvax swarm (but resulted in lower neurotoxicity in mice) was 
selected (220). This virus, grown in cell culture, was shown to protect animals against 
orthopoxvirus infections (220-222). Ultimately, this virus, called ACAM2000, became 
the FDA licensed smallpox vaccine in the U.S (223,224). However, like Dryvax, this 
vaccine generates infectious progeny that can spread within the host, and thus it is 
expected to result in the same minor and major complications of the parent virus 
(225,226). Therefore, the prescribing package insert for ACAM2000 contains the same 
warnings as Dryvax indicating that people with immunodeficiencies, common skin 
disorders like eczema and atopic dermatitis, cardiac disease, age less than 12 months, and 
pregnancy are still at risk for developing a severe complication from the vaccine and 
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should not get vaccinated in the setting where there is no active smallpox (227). Because 
of the concerns about complications from the smallpox vaccine, there has been a 
continued interest in developing safer smallpox vaccines that can be used in a diverse 
population, including people at risk for the severe complications from current live 
vaccinia virus vaccines. 
 
Development of more attenuated live virus vaccines 
Prior to the eradication of smallpox, some countries began testing more attenuated 
strains of vaccinia virus as potential smallpox vaccines. These vaccines were isolated by 
continual passage of a parental vaccine strain in cell culture, which resulted in random 
mutations that attenuated the virus. Many of these vaccines were given to large 
populations and appeared to have less side effects, but were used in countries where 
smallpox disease no longer existed. Examples of this strategy are LC16m8 and MVA 
strains of vaccinia virus. 
 
LC16m8 
In Japan, LC16m8 was developed as an attenuated vaccinia virus vaccine (228-
230). This virus was isolated after passage of the parental Lister strain of vaccinia virus in 
rabbit cells at low temperature. The resulting virus made very small plaques in cell 
culture and showed less neurovirulence in animal models. Much of the attenuated 
phenotype of this virus is due to a mutation in the B5R gene (231), which encodes for an 
important glycoprotein needed for the optimal production of an infectious form of virus 
critical for virus spread. Thus, while LC16m8 can grow and make infectious particles, it 
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spreads poorly in cell culture. LC16m8 has been shown to generate protective immunity 
in mice (232), rabbits (232), and non-human primates (233). However, there are two 
important concerns about this vaccine. Since the key attenuating mutation in B5R is a one 
base deletion that results in a frame-shift and early truncation of the B5 protein (231), 
there is evidence that virus can revert back to wild type during growth (234). An 
additional concern is that the B5 protein is an important protective target of the humoral 
immune response to live vaccinia virus vaccination (113,129) and this aspect of 
protection may be lost in an LC16m8 vaccinated individual. 
 
Modified vaccinia Ankara (MVA) 
In Germany, modified vaccinia Ankara (MVA) was developed as a highly 
attenuated potential smallpox vaccine (235,236). This vaccine was obtained after 572 
serial passages of the parental vaccinia strain on chick embryo fibroblasts. This resulted 
in about 25 kilobases deleted and a virus that no longer produced infectious progeny virus 
in almost all mammalian cell lines. That is, the virus could infect, replicate its DNA, and 
generate abundant amounts of key viral proteins, but could not assemble into infectious 
virions in most mammalian cells. Because of the inability to generate infectious virions in 
human cells, this type of virus would likely be safe to give to many people who have 
conditions that would not allow routine smallpox vaccination. Therefore, this virus has 
been intensively studied as a next generation smallpox vaccine that may ultimately gain 
FDA approval in the U.S.A. The virus has been widely studied and shown to generate 
antibody responses similar to Dryvax (130), as well as protection in mouse (237,238) and 
non-human primate challenge models (104,239,240). There is evidence that MVA 
 33 
vaccination results in more rapid protection when compared to a fully replication 
competent vaccine, like Dryvax (241). While the mechanism for this enhanced early 
protection by MVA is not entirely known, part of the explanation may be that it induces 
more rapid immunity (241) because it is given at about a 1000-times higher dose than 
current replication competent vaccinia vaccines. It also appears that MVA can activate 
innate immune responses because it is missing genes present in replication competent 
vaccinia virus that encode proteins that may initially dampen the immune response 
(87,242). 
 
Subunit-based vaccines 
Until recently, it was believed that protection conferred by live vaccinia virus 
vaccination was predominantly due to anti-vaccinia T cell responses. This was mainly 
based on the fact that inactivated smallpox vaccines did not protect against smallpox (3). 
Thus, it was assumed that live vaccinia virus vaccination protected by potent anti-viral T 
cell responses. However, the inability of experimental inactivated vaccines to protect may 
have been due to denaturing of key targets (243), as well as the fact that the vaccine 
preparations did not contain some critical antigens that are present on a minor population 
of infectious virus (116,244). Furthermore, in recent years protection via vaccination with 
live vaccinia virus has been shown to be dependent on vaccinia specific, CD4+ dependent 
B-cell responses (94,100,107,245). Thus, future-generation smallpox vaccines that are 
capable of inducing protective antibody responses are viable alternatives to the current 
live-virus vaccines. One way to induce such antibody responses is to provide protein(s) 
directly to the immune system to which neutralizing and protective antibodies can be 
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generated. Strategies to present these critical proteins include direct injection of soluble 
proteins with adjuvants, introduction of recombinant DNA that host cells transcribe and 
translate, and live or attenuated vectors that deliver poxvirus proteins to the host immune 
system. 
Since poxviruses are large DNA viruses that encode over 200 proteins, the 
identification of suitable proteins that would generate a protective immune response is 
complex. Most research has focused on different surface membrane proteins of the two 
infectious forms of virus, the mature virus (MV) and the extracellular virus (EV) (31,34). 
Furthermore, including targets against both MV and EV appears to provide the best 
protection from morbidity and mortality (98,110,138,160,246). Including targets against 
both forms of infectious virus is believed to provide a way to decrease the infecting 
inoculum (believed to be mainly MV) and then alter the spread and dissemination of the 
virus within an infected host (thought to be mainly EV) (73,247-250). Initial insights into 
appropriate targets against MV and/or EV proteins were based on the production of 
antibodies that could neutralize virus in vitro or provide passive protection against 
vaccinia virus challenge in vivo (28,96,109,145-147,154,160,166,251-254). Relevant 
protein targets were also identified by examining what proteins were recognized by 
vaccinia immunoglobulin (VIG) (113,115,127-129), serum from vaccinia virus 
vaccinated individuals that was used clinically to treat complications from live vaccinia 
virus vaccination. Many of the protein targets identified by these approaches are targets 
of potent neutralizing antibodies. The following sections and tables will cover the most 
widely studied viral targets and the effort that is being made to combine these targets into 
effective subunit vaccines. 
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Protein-based subunit vaccines 
The first successful attempt at a subunit vaccine to protect against lethal vaccinia 
virus challenge was by Lai, et al. in 1991 (139). They intraperitoneally injected purified 
vaccinia virus A27 protein (an MV protein) generated in Escherichia coli and found that 
the antibody response generated was both MV neutralizing in vitro, and 100% protective 
against a lethal intraperitoneal challenge with vaccinia virus. The EV proteins, A33 and 
B5, produced in baculovirus were first shown to generate protective immune responses 
by Galmiche (109). They found that injection of A33 or B5 protein provided 100% 
protection from lethal intranasal challenge with vaccinia virus. While only B5 
vaccination elicited in vitro EV neutralizing activity, the antibodies produced against A33 
resulted in “comet inhibition”, indicating that they altered the way EV spread in cell 
culture. Antibody to A33 may also provide protection through the activation of 
complement (97). Table 2-1 summarizes the individual orthopoxvirus genes that have 
been examined as a subunit vaccine. Proteins have been expressed in bacteria 
(94,99,101,109,139,162,255), baculovirus (98,105,109,110), and even recombinant plants 
(168). 
While work with individual proteins has helped identify appropriate targets to 
include in a subunit vaccine, the combination of multiple proteins is believed to provide 
the optimum protection (Table 2-2). For example, A33, B5, and L1 proteins have been 
used in combination to generate a mouse antibody response to both the MV and EV 
infectious forms of vaccinia virus (98,110). These trivalent subunit vaccines provide 
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Table 2-1. Individual gene targets 
 
Gene(s) 
(target) Origin Delivery Adjuvant Animal Model 
Challenge 
Virus/Route/Dose Survival/Morbidity 
Correlates of Protection 
Investigated Reference 
A13L 
(MV) 
VACV, IHD-J 
strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 0%/severe No antibody detected (169) 
A27L 
(MV) 
VACV, WR 
strain 
Protein (expressed in 
bacteria), i.p., 2 doses 
Prime: Freund’s 
complete, Boost: 
Freund’s 
incomplete 
BALB/c mice VACV, WR strain/i.p./1.5E8 pfu/mo 100%/ND MV NAb (139) 
 
VACV, 
NYBH-CONN 
strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated on 
gold 
BALB/c mice VACV, WR/i.p./5E8 pfu/mo 10%/severe MV NAb (138) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 80%/significant No antibody detected (169) 
 CPXV 
VEE virus replicon 
(VRP), 2 doses of 1E6 
IU VRP 
none BALB/c mice 
CPXV, Brighton 
red/i.n./1E6 pfu/mo 
(sublethal dose) 
100%/significant Anti-VACV antibody, Th1 response (IgG2a dominant) (256) 
 VARV 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c VACV, WR strain/i.p./5E7 pfu/mo 100%/moderate MV NAb (162) 
 VACV, WR strain 
Replication incompetent 
rAd35 vector, 1 dose none BALB/c mice 
VACV, WR 
strain/i.p./2E8 pfu/mo i.p.: 50%/severe 
Anti-VACV antibody, not 
comet inhibitory, Th1/Th2 
balanced response (IgG2a and 
IgG1 both produced), IFNγ 
producers detected 
(246) 
A33R 
(EV) 
VACV, IHD-J 
strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Primary: 
Freund’s 
complete / 
Boosts: Freund’s 
incomplete 
BALB/c mice VACV, IHD-J strain/i.n./1E7 pfu/mo 100%/significant Anti-VACV antibody (109) 
 VACV, IHD-J strain DNA, i.m., 4 doses None BALB/c mice 
VACV, IHD-J 
strain/i.n./1E6 pfu/mo 100%/significant 
Anti-VACV antibody, 
protection not correlated with 
titers  
(109) 
 
VACV, 
NYBH-CONN 
strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated on 
gold 
BALB/c mice VACV, WR/i.p./5E8 pfu/mo 0%/severe Anti-VACV antibody (160) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./1E6 pfu/mo 
or 2E7 pfu/mo 
1E6: 100%/mild 
2E7: 70%/severe 
Anti-VACV antibody, Th2 
response (IgG1 dominant), 
comet inhibitory 
(98) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 67%/significant Anti-VACV antibody (169) 
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 ECTV (EVM135) 
Protein (expressed in 
bacteria), s.c., 2 doses 
Freund’s 
incomplete BALB/c mice 
ECTV/footpad/3000pfu/
mo 70%/moderate 
Anti-VACV antibody, comet 
inhibitory, antigen specific 
CD8+ T cells 
(101) 
 CPXV VRP, 2 doses of 1E6 IU none BALB/c mice 
CPXV, Brighton 
red/i.n./1E6 pfu/mo 
(sublethal dose) 
100%/moderate Anti-VACV antibody, Th1 response (IgG2a dominant) (256) 
 VACV, WR strain 
Replication incompetent 
rAd35 vector, 1 dose none BALB/c mice 
VACV, WR 
strain/i.p./2E8 pfu/mo 
i.p.: 75%/moderate 
to severe 
Anti-VACV antibody, not 
comet inhibitory, Th1/Th2 
balanced response (IgG2a and 
IgG1 both produced), IFNγ 
producers detected 
(246) 
A34R 
(EV) 
VACV, IHD-J 
strain 
Protein (expressed in 
bacteria), s.c., 4 doses 
Primary: 
Friend’s 
complete / 
Boosts: Friend’s 
incomplete 
BALB/c mice VACV, IHD-J strain/i.n./1E7 pfu/mo 0%/severe NR (109) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J 
strain/i.n./1E6 pfu/mo ~20%/severe NR (109) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 0%/severe No antibody detected (169) 
A36R 
(Cell*) 
VACV, IHD-J 
strain 
Protein (expressed in 
bacteria), s.c., 4 doses 
Primary: 
Friend’s 
complete / 
Boosts: Friend’s 
incomplete 
BALB/c mice VACV, IHD-J strain/i.n./1E7 pfu/mo 0%/severe NR (109) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J 
strain/i.n./1E6 pfu/mo ~50%/very severe NR (109) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 60%/significant No antibody detected (169) 
A56R 
(EV) 
VACV, IHD-J 
strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 50%/significant Anti-VACV antibody (169) 
B5R 
(EV) 
VACV, IHD-J 
strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Primary: 
Friend’s 
complete / 
Boosts: Friend’s 
incomplete 
BALB/c mice VACV, IHD-J strain/i.n./1E7 pfu/mo ~90%/severe Anti-VACV antibody (109) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J 
strain/i.n./1E6 pfu/mo ~80%/significant NR (109) 
 
VACV, 
NYBH-CONN 
strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated on 
gold 
BALB/c mice VACV, WR/i.p./5E8 pfu/mo 40%/severe 
Anti-VACV antibody, non-MV 
NAb (138) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./1E6 pfu/mo 
or 2E7 pfu/mo 
1E6: 
100%/moderate 
2E7: 30%/severe 
Anti-VACV antibody, Th2 
response (IgG1 dominant) (98) 
 38 
 VACV, IHD-J strain DNA, i.m., 3 or 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 100%/moderate 
Anti-VACV antibody, IFNγ -
Type I response (169) 
 VACV, WR strain 
Protein (expressed in 
planta), i.m., 3 doses CpG, alum BALB/c mice 
VACV, WR 
strain/i.n./1.2E6 pfu/mo 100%/severe 
Anti-VACV antibody, comet 
inhibitory (168) 
 CPXV VRP, 2 doses of 1E6 IU none BALB/c mice 
CPXV, Brighton 
red/i.n./1E6 pfu/mo 
(sublethal) 
100%/significant Anti-VACV antibody, Th1 response (IgG2a dominant) (256) 
 VARV 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice VACV, WR strain/i.p./5E7 pfu/mo 100%/significant Anti-VACV antibody (162) 
 VACV, WR strain 
Replication incompetent 
rAd35 vector, i.m., 1 
dose 
none BALB/c mice 
VACV, WR strain/i.p. 
or i.n./i.p.: 2E8 pfu/mo, 
i.n.: 2E7 pfu/mo 
i.p.: ~90%/severe 
i.n.: 75%/severe 
Anti-VACV antibody, comet 
inhibitory, Th1/Th2 balanced 
response (IgG2a and IgG1 both 
produced), minimal IFNγ 
producers detected 
(246) 
 CPXV, de novo synthesis 
Replication incompetent 
rAd5 vector, i.m., 1 
dose 
none BALB/c mice 
3 months post 
vaccination: VACV, 
WR strain/i.n./1E5 
pfu/mo (sublethal) 
100%/moderate Anti-VACV antibody, comet inhibitory (257) 
 CPXV, de novo synthesis rVSV, i.m., 1 dose none BALB/c mice 
3 months post 
vaccination: VACV, 
WR strain/i.n./1E5 
pfu/mo (sublethal) 
53%/significant Anti-VACV antibody, slightly comet inhibitory (257) 
 CPXV, de novo synthesis 
Replication incompetent 
rAd5 vector prime, 
rVSV boost, i.n., 1 dose 
each 
none BALB/c mice 
3 months post 
vaccination: VACV, 
WR strain/i.n./1E5 
pfu/mo (sublethal) 
100%/mild Anti-VACV antibody, comet inhibitory (257) 
B18R/ 
EVM1
66 
(IRM) 
ECTV Protein (expressed in bacteria), i.m., 3 doses none BALB/c mice 
ECTV/Footpad/300pfu/
mo(60xLD) 
100%/mild to 
moderate 
Anti-ECTV antibody, 
neutralized protein activity (82) 
D8L 
(MV) 
VACV, IHD-J 
strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 50%/severe Anti-VACV antibody (169) 
 VACV, WR strain 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice VACV, WR strain/i.p./5E7 100%/moderate MV NAb (153) 
 VARV 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice VACV, WR strain/i.p./5E7 pfu/mo 100%/moderate MV NAb (162) 
H3L 
(MV) 
VACV, IHD-J 
strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 33%/severe No antibody detected (169) 
 VACV, WR strain 
Protein (expressed in 
bacteria), i.m., 2 doses Ribi BALB/c mice 
VACV, WR 
strain/i.n./~5E5 pfu/mo 
or ~2.5E7 pfu/mo 
~5E5:100%/signific
ant 
~2.5E7:0%/severe 
MV NAb (99) 
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L1R 
(MV) 
VACV, 
NYBH-CONN 
strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated on 
gold 
BALB/c mice VACV, WR/i.p./5E8 pfu/mo 89%/significant MV NAb (160) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./1E6 pfu/mo 
or 2E7 pfu/mo 
1E6: 
100%/moderate 
2E7: 30%/severe 
MV NAb, Th2 response (IgG1 
dominant) (98) 
 
VACV, 
NYBH-CONN 
strain 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
DNA 
precipitated on 
gold 
NHP MPXV/ i.v./ 2E7 pfu per NHP 100%/severe MV NAb (106) 
 VACV, IHD-J strain DNA, i.m., 4 doses none BALB/c mice 
VACV, IHD-J strain/ 
i.n./1E7 pfu/mo 0%/severe No antibody detected (169) 
 VACV, WR strain 
Replication incompetent 
rAd35 vector, 1 dose none BALB/c mice 
VACV, WR strain/i.p. 
or i.n./i.p.: 2E8 pfu/mo, 
i.n.: 2E7 pfu/mo 
i.p.: 100%/mild 
i.n.: 75%/severe 
MV NAb, not comet 
inhibitory, Th1/Th2 balanced 
response (IgG2a and IgG1 both 
produced), IFNγ producers 
detected 
(246) 
Abbreviations used in Table: 
alum, aluminum hydroxide 
Cell*, A36 is a viral protein expressed on an infected cell that helps direct MV to become EV. 
CPXV, cowpox virus (Brighton red strain) 
ECTV, ectromelia virus (Moscow strain) 
IHD-J, International Health Department strain J of VACV 
i.d., intradermal 
i.m., intramuscular 
i.p., intraperitoneal 
IRM, immune response modifiers 
i.v., intravenous 
MPXV, monkeypox (Zaire 79 strain) 
MV, mature virus 
NAb, neutralizing antibody 
ND, not done 
NHP, non-human primate 
NR, not reported 
NYBH-CONN, New York Board of Health-Connaught strain 
pfu/mo, plaque-forming unit per mouse 
QS21, non-toxic saponin derived from the soapbark tree, Quillaja saponaria 
rAd, recombinant adenovirus 
Ribi, MPL+TDM (monophosphoryl lipid A + trehalose dicorynomycolate) adjuvant 
rVSV, recombinant Vesicular stomatitis virus 
s.c., subcutaneous 
VACV, vaccinia virus 
VARV, variola virus (India 1967 strain) 
VRP, Venezuelan equine encephalitis (VEE) virus replicon particle 
WR, western reserve strain of vaccinia virus 
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Table 2-2. Combination Gene Targets 
Genes Origin Delivery Adjuvant Animal Model 
Challenge 
Virus/Route/Dose Survival/Morbidity Correlates of Protection Investigated Reference 
A27L, 
A33R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, IHD-J strain/ 
i.p./5E8 pfu/mo 70%/severe Anti-VACV antibody (138) 
A27L, 
B5R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, IHD-J strain/ 
i.p./5E8 pfu/mo 95%/significant MV NAb (138) 
 VACV, WR strain 
Protein (expressed in 
bacteria), s.c., 3 doses 
Ribi or 
TiterMax 
gold 
adjuvant 
BALB/c 
mice 
VACV, WR 
strain/i.n./~2.4E6 
pfu/mo 
100%/significant 
MV NAb, comet inhibitory, Th1/Th2 
balanced response in Ribi (equal IgG1 and 
IgG2a, Th2 response in TiterMax adjuvant 
(IgG1 dominant), Cd8+ and CD4+ 
responses 
(255) 
A27L, 
L1R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, IHD-J strain/ 
i.p./5E8 pfu/mo 40%/severe MV NAb (138) 
A33R, 
B5R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, IHD-J strain/ 
i.p./5E8 pfu/mo 80%/severe Anti-VACV antibody (138) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./ 2E7 
pfu/mo 
90%/severe Anti-VACV antibody, Th2 response (IgG1 dominant), comet inhibitory (98) 
A33R, 
L1R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, WR/i.p./5E8 
pfu/mo 100%/mild MV NAb (160) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./ 2E7 
pfu/mo 
90%/moderate MV NAb, Th2 response (IgG1 dominant), comet inhibitory (98) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 2 doses 
alum, or 
alum + CpG, 
or Ribi, or 
QS21 
BALB/c 
mice 
VACV, WR 
strain/i.n./2E7 
pfu/mo 
alum: 50%/severe, 
alum + CpG: 
100%/moderate, 
Ribi: 
80%/significant, 
QS21: 100%/mild 
MV Nab (except alum – some anti-VACV 
antibody), comet inhibitory, Th1/Th2 
balanced response in alum + CpG or Ribi 
(except for anti-L1) or QS21 (equal IgG1 
and IgG2a), Th2 response in alum (IgG1 
dominant) 
(105) 
B5R, 
L1R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, IHD-J strain/ 
i.p./5E8 pfu/mo 100%/moderate Weakly MV NAb (138) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
s.c., 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./ 2E7 
pfu/mo 
60%/severe MV NAb, Th2 response (IgG1 dominant) (98) 
A27L, 
A33R, 
B5R 
VACV, WR 
strain 
Protein (expressed in 
baculovirus system), 
i.m., 2 doses 
CpG, alum BALB/c mice 
VACV, WR 
strain/i.n./~6E6 
pfu/mo 
VACV: 
~20%/severe Weak MV NAb, comet inhibitory (110) 
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 CPXV VRP, 2 doses of 1E6 IU none BALB/c mice 
CPXV, Brighton 
red/i.n./1E6 pfu/mo 
(sublethal dose) 
100%/mild Anti-VACV antibody, Th1 response (IgG2a dominant) (256) 
A27L, 
B5R, 
D8L 
VACV, WR 
strain 
Protein (expressed in 
bacteria), s.c., 3 doses 
Ribi or 
TiterMax 
gold 
adjuvant 
BALB/c 
mice 
VACV, WR 
strain/i.n./~2.4E6 
pfu/mo 
100%/significant 
MV NAb, comet inhibitory, Th1/Th2 
balanced response in Ribi (equal IgG1 and 
IgG2a), Th2 response in TiterMax 
adjuvant (IgG1 dominant), Cd8+ and CD4+ 
responses 
(255) 
 VARV Protein (expressed in bacteria), 2 doses 
Freund’s 
incomplete 
BALB/c 
mice 
VACV, WR 
strain/i.n./5E6 
pfu/mo 
100%/ND Anti-VACV antibody, neutralization ND (162) 
 VARV 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice 
VACV, WR 
strain/i.p./5E7 
pfu/mo 
100%/mild MV NAb (162) 
 VARV 
DNA, gene gun 
(abdominal epidermis), 
2 doses 
none BALB/c mice 
VACV, WR 
strain/i.n./5E6 
pfu/mo 
80%/ND MV NAb (162) 
A33L, 
B5R, 
L1R 
VACV, WR 
strain 
Protein (expressed in 
baculovirus system), 
s.c., 3 or 4 doses 
Ribi or QS21 BALB/c mice 
VACV, WR 
strain/i.n./ 2E7 
pfu/mo 
100%/mild MV NAb, Th2 response (IgG1 dominant), comet inhibitory (98) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
i.m., 4 doses 
QS21 NHP 
MPXV/i.v./5E7 
(sublethal dose in this 
study) 
100%/moderate VACV MV Nab, MPXV MV Nab, VACV comet inhibitory, MPXV comet inhibitory (105) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
i.m., 2 doses 
CpG, alum BALB/c mice 
VACV, WR 
strain/i.n./~6E6 
pfu/mo OR 
ECTV/i.n./1000 
pfu/mo 
VACV: 100%/mild 
ECTV: 100%/mild MV NAb, comet inhibitory (110) 
A27L, 
A33R, 
B5R, 
L1R 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
3 doses 
DNA 
precipitated 
on gold 
BALB/c 
mice 
VACV, IHD-J strain/ 
i.p./5E8 pfu/mo 100%/mild Anti-VACV antibody (138) 
 
VACV, 
NYBH-
CONN strain 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
DNA 
precipitated 
on gold 
NHP MPXV/ i.v./ 2E7 per NHP 100%/mild MV NAb (106) 
 
VACV, 
NYBH-
CONN strain 
DNA, Skin 
Electroporation Device, 
3 doses 
none BALB/c mice 
VACV, IHD-J/ 
i.n./2E6 per muse 100%/mild 
MV NAb, Th1/Th2 balanced response 
(IgG2a and IgG1 detected) (161) 
 VACV, WR strain 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice 
VACV, WR 
strain/i.n./5E6 per 
mouse 
26%/significant MV NAb (153) 
 MPXV DNA, i.m. and i.d., 3 doses none NHP MPXV/i.v./5E7 pfu 0%/severe 
Weak Anti-VACV antibody, non-MV 
NAb, no CD8+ or CD4+ response (149) 
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 MPXV Protein, i.m., 3 doses alum or CpG NHP MPXV/i.v./5E7 pfu 100%/mild to severe 
VACV MV NAb, MPXV MV NAb, 
MPXV EV NAb, CpG adjuvant gave a 
CD8+ and CD4+ response 
(149) 
 MPXV 
DNA, i.m. and i.d., 3 
doses/ Boosted with 
protein, i.m., 3 doses 
Protein in 
CpG NHP MPXV/i.v./5E7 pfu 100%/mild 
VACV MV NAb, MPXV MV NAb, 
MPXV EV NAb, Detectable CD8+ and 
CD4+ response (IL-2+ and IFNγ+/TNFα+ 
(149) 
 VACV, WR strain 
Protein (expressed in 
baculovirus system), 
i.m., 2 doses 
CpG, alum BALB/c mice 
VACV, WR 
strain/i.n./~6E6 
pfu/mo OR 
ECTV/i.n./1000 
pfu/mo 
VACV: 100%/mild 
ECTV: 100%/mild MV NAb, comet inhibitory (110) 
 VACV, WR strain 
Replication incompetent 
rAd35 vector, 1 dose none 
BALB/c 
mice 
VACV, WR 
strain/i.p. or i.n./i.p.: 
2E8 pfu/mo, i.n.: 2E7 
pfu/mo 
i.p.: 100%/mild 
i.n.: 100%/mild to 
moderate 
MV NAb, comet inhibitory, Th1/Th2 
balanced response (IgG2a and IgG1 both 
produced), IFNγ producers detected 
(246) 
A27L, 
A33R, 
B5R, 
L1R, 
D8L 
VACV, WR 
strain 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice 
VACV, WR 
strain/i.p./5E7 per 
mouse 
100%/mild MV NAb (153) 
 VACV, WR strain 
DNA, gene gun 
(abdominal epidermis), 
4 doses 
none BALB/c mice 
VACV, WR 
strain/i.n./5E6 per 
mouse 
66%/moderate MV NAb (153) 
Abbreviations used in Table - see Table 2-1. 
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100% protection from a lethal intranasal challenge with vaccinia virus in BALB/c mice 
with only mild disease (as measured by weight loss). This protection was achieved with 
as little as 2 doses given only 2 weeks apart and challenge of the mice 3 weeks after the 
boost vaccination (110). Addition of the A27 protein to the other three proteins to form a 
tetravalent vaccine provided little additional benefit in mice (110). This is a remarkable 
achievement considering that an immune response to only 3 proteins can provide 
protection from a virus that encodes 200 proteins. In addition to these 4 proteins, other 
MV targets of neutralizing antibodies such as D8 and H3 have been explored, though 
they have not been shown to greatly enhance the ability of the trivalent protein vaccine 
(A33, B5, L1) to protect against disease symptoms (99,255). 
The focus of protein subunit vaccination has mainly been on the envelope proteins 
of poxviruses that would target the infectious forms of the virus. However, poxviruses 
also encode a large assortment of non-structural proteins that encode immune response 
modifiers (IRMs) (258). These proteins allow poxviruses to dampen or alter the immune 
response of the host, in order to more efficiently spread throughout the host and 
ultimately infect the next host. Xu et al. (82) identified that the interferon (IFN) α/β 
binding protein encoded by the orthopoxvirus ectromelia virus (ECTV) EVM166 gene 
was critical for the efficient replication and spread of ECTV within its natural host, the 
mouse. With this in mind, they vaccinated mice with purified EVM166 protein to induce 
an antibody response that could neutralize the protein’s biological activity. They found 
that vaccinated mice challenged with a lethal dose of ECTV (by a footpad infection) were 
protected against death with only mild to moderate disease symptoms (82). This was the 
first demonstration that a non-structural protein could be used in a subunit vaccine to 
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interfere with the ability of a virus to modulate the host immune response. This approach 
may be useful in future subunit smallpox vaccines, although it would be critical to 
determine which IRMs are most important for the replication and spread of smallpox. 
While subunit vaccines have shown protection from vaccinia virus challenge, it is 
also important to show the ability of a vaccine to protect against a viral challenge in its 
natural host. Thus, the ectromelia virus (mousepox) challenge of mice has been a useful 
model since ECTV is a natural pathogen of the laboratory mouse (Mus musculus). Fang, 
et al. found that immunization with 2 doses of a single EV protein, A33, could partially 
protect BALB/c mice from death with a lethal dose of ECTV by footpad (101). By 
combining EV and MV targets, protein vaccinations with A33, B5, and L1, were able to 
fully protect against an intranasal ECTV challenge with only mild disease symptoms 
observed (110). 
A monkeypox model of poxvirus infection has also been studied using protein 
vaccination. This model is important because monkeypox represents a known human 
pathogen, and it is believed that if monkeys can be protected from monkeypox it is likely 
that a similar immune response in humans could provide similar protection. Due to the 
expense of non-human primate studies and the need to have a model with a reproducible 
outcome of death in unvaccinated controls, the monkeypox model in non-human primates 
has focused on a high dose intravenous challenge (104). There are obvious disadvantages 
of this model. One disadvantage is that the high dose intravenous challenge bypasses the 
natural acquisition and spread of the virus in the host and is thought to reproduce mainly 
the stage of secondary viremia. Thus, this type of challenge sets a very high hurdle for a 
vaccine to show protection since natural acquisition of infection is likely caused by a 
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much lower dose that may be more easily controlled by vaccination. Of equal concern is 
that an intravenous challenge may accentuate the protection of vaccines that rely mainly 
on antibody responses that neutralize the incoming virus. Nevertheless, protein 
vaccination has been shown to protect monkeys from challenge. Heraud, et al., injected 
the monkeypox orthologs of A27, A33, B5, and L1 into rhesus macaques and found that 
these monkeys were completely protected from death with a lethal intravenous challenge 
with monkeypox, though they exhibited varying degrees of morbidity (149). Similarly, a 
small pilot study with the vaccinia virus A33, B5, and L1 proteins showed protection 
from severe disease after monkeypox challenge (105). Future studies using the 
monkeypox model will need to examine vaccine protection using more natural modes of 
challenge and will have to determine if adjustments in the vaccine formulation could 
enhance protection.  
Protein vaccination, in general, requires proper formulation in order to induce an 
effective immune response to the injected antigens. Varying the source of protein, 
amounts of protein, site of injection, and adjuvant can all play a role in the ability of the 
protein vaccination to elicit a potent and effective immune response. Live vaccinia virus 
vaccination with a fully protective vaccine like Dryvax resulted in Th1-type cellular and 
humoral responses (98,259). For protein vaccination, appropriate adjuvants that skew the 
immune response towards a Th1-type response were shown to produce the best protection 
from both morbidity and death (105,110,149,168). 
While live vaccinia virus vaccination provides cross-protection against various 
orthopoxvirus infections, there is concern that a subunit smallpox vaccine based on 
vaccinia virus proteins might miss important epitopes present in the variola virus ortholog 
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proteins. Compared to live virus vaccination, the small differences of just a few amino 
acids between the vaccinia virus and variola virus proteins may be amplified in a subunit 
vaccine that relies on just a few proteins to confer protection. For example, anti-B5 
monoclonal antibodies have revealed that there are protective epitopes on the vaccinia B5 
protein that are not present on the variola B5 ortholog (167). Similar findings have been 
reported with differences between the vaccinia virus A33 protein and the monkeypox 
A33 ortholog (254). Thus, another strategy that is being pursued by many groups is to use 
the variola virus (VARV) protein orthologs. For example, vaccination with smallpox 
orthologs of the vaccinia virus A27, B5, and D8 proteins provided complete protection 
from vaccinia virus challenge (162). Importantly, in this study it was found that the 
antibodies induced were at least as efficient at binding VARV protein as their vaccinia 
virus counterparts. Further studies will be needed to determine if VARV proteins can 
provide greater protection against smallpox virus than vaccinia virus proteins can confer. 
 
DNA-based subunit vaccines 
DNA vaccination involves the introduction of recombinant DNA plasmids that 
encode relevant protein antigens (260). The DNA plasmid is introduced into mammalian 
cells at the injection site, where the protein is then expressed. This is thought to have a 
number of advantages over simply vaccinating with a purified protein: (1) Using the 
normal host cell machinery to produce the protein, rather than using bacterial or 
baculovirus produced proteins, may create a more antigenetically authentic protein to 
what would be made during a natural infection; (2) By producing the protein within cells, 
it may generate a stronger T cell response through normal MHC class I presentation; (3) 
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Multiple gene targets can be easily included in a vaccine; and (4) Lyophilized DNA can 
be stored at room temperature for long periods of time without degradation. These 
advantages have led a number of laboratories to pursue subunit DNA smallpox vaccines. 
Galmiche, et al. were the first to demonstrate that protective responses could be 
generated by A33R or B5R DNA vaccines (109). Similar to what they found with protein 
vaccination, intramuscularly injecting DNA encoding either the A33 or B5 protein (but 
without the need for additional adjuvants), resulted in 100% survival of vaccinia virus 
challenged mice. This work led Hooper, et al. to create a bivalent DNA vaccine encoding 
both the MV and EV proteins L1 and A33. Using a “gene gun”, a device created to inject 
DNA coated on gold beads, they were able to show 100% survival and only mild disease 
symptoms after challenge by the intraperitoneal route with a lethal dosage of vaccinia 
virus (160). Hooper, et al. later expanded upon this work by including the A27L and B5R 
genes to make a tetravalent vaccine (138). While they found that a bivalent A27L and 
B5R DNA vaccine did not give complete protection, the tetravalent vaccine (A27L, 
A33R, B5R, L1R) gave complete protection from a lethal intraperitoneal vaccinia virus 
challenge with only mild disease symptoms (138). Pulford, et al. used DNA vaccines 
against single MV and EV vaccinia virus protein targets to determine if they could 
provide protection from an intranasal challenge with vaccinia virus (169). In addition to 
showing that the B5R DNA vaccine offered 100% protection from challenge, they also 
demonstrated that smallpox subunit DNA vaccines could induce an IFNγ response and a 
memory response mediated by a CD4+ T cell population (169). To determine if additional 
antigen targets would be beneficial in a polyvalent vaccine, Sakhatskyy et al. (153) added 
a fifth gene, D8L, to the tetravalent DNA vaccine formulation used by Hooper, et al. 
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(138). They found that adding the D8L gene to the other four vaccinia virus genes offered 
better protection in an intranasal model of challenge than without it, though protection 
was not 100% (153). Additionally, Sakhatskyy et al. determined that using the VARV 
homologs of A27L, B5R, and D8L partially protected mice from a lethal intranasal 
vaccinia virus challenge (162). As discussed previously, the additional use of VARV 
sequence to construct a vaccine may be important to ensure immune reactivity in the face 
of a smallpox challenge. 
The lack of complete protection from morbidity seen by some investigators with 
the polyvalent DNA vaccines (Table 2-2) could be due to the method of DNA delivery 
and the type of immune response that was generated. To determine if this was the case, 
Hooper, et al. used a novel method of skin electroporation to deliver their DNA vaccine 
(161). They found that this method of delivery improved the efficacy of their tetravalent 
DNA vaccine (A27L, A33R, B5R, L1R), and provided complete protection from 
challenge in an intranasal model of infection. They found that skin electroporation 
mimicked to a greater extent the type of antibodies produced during Dryvax vaccination, 
by inducing more mouse IgG2a antibodies (Th1 response), than the gene gun method of 
DNA delivery (161). This finding makes the skin electroporation method a more 
attractive method of DNA delivery than the gene gun method. The mode of vaccination 
was further highlighted by work in non-human primates. Hooper, et al. found that they 
could generate complete protection from an intravenous monkeypox virus challenge 
using their tetravalent (A27L, A33R, B5R, and L1R) formulation delivered by a gene gun 
(106). However, Heraud et al. found that when the monkeypox homologs of A27L, 
A33R, B5R, and L1R were injected as naked DNA, there was no protection from 
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monkeypox challenge (149). Going forward, DNA vaccines will need to be administered 
in a way best able to generate a Th1-type immune response that includes both 
neutralizing antibodies and strong T cell responses. 
 
Vector-based subunit vaccines 
Vectored vaccines utilize a non-pathogenic virus or bacteria to deliver a desired 
antigen. Because protein and DNA vaccinations have been shown to require multiple 
vaccinations to achieve protective immunity, vectored vaccines have been pursued as a 
way to generate a smallpox vaccine that can offer protection in a single vaccination. In a 
smallpox outbreak setting, it would be important to induce protective immunity as rapidly 
as possible to avoid spread of the virus. The first laboratory to explore vector subunit 
smallpox vaccines utilized replicon particles of Venezuelan equine encephalitis virus 
(256). By expressing A27, A33, and B5, they generated a strong mouse IgG2a antibody 
response (Th1-type response) and protected mice from a sublethal dose of cowpox virus. 
Kaufman et al, utilized replication incompetent recombinant Adenovirus serotype 35 
(rAd35) vectors expressing A27, A33, B5 and L1 antigens (246). By delivering a single 
immunization with all four rAd35 vectors, they were able to achieve complete protection 
in mice from a lethal intranasal vaccinia virus challenge. The rAd35 vaccine generated 
strong MV neutralizing antibodies that were balanced between mouse IgG2a and IgG1 
antibodies (Th1 and Th2 response) (246). Vectored vaccines so far appear to be a 
promising delivery method for subunit smallpox vaccines, but much work is still needed 
to determine the immunogenicity and safety profile in non-human primates and humans. 
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Conclusions 
While stockpiling of a live vaccinia virus vaccine grown in cell culture has been 
successful, significant concerns about the minor and major complications from this 
vaccine remain, especially in populations that have contraindications for vaccination. 
More attenuated live vaccinia virus vaccines, which will be much safer to give to a 
diverse population, will likely be the next new generation smallpox vaccine that gains 
regulatory approval. However, growing and maintaining a stock of a live virus vaccine, 
as well as the potential for adverse events, are limitations that fuel the continued pursuit 
of future generation smallpox vaccines. Subunit vaccines are showing great success. 
Many possibilities for protective vaccines exist and future efforts to directly compare 
different vaccination strategies will be needed. For example, Barefoot, et al. chose a 
single immunogen, B5, and compared multiple vaccination strategies for generating 
immune responses and examined the level of protection from challenge (257). They 
found that a heterologous prime-boost combination of recombinant vesicular stomatitis 
virus (rVSV) expressing B5 and recombinant Venezuelan equine encephalitis virus 
replicons (VRP) expressing B5 as the most synergistic regimen. A possible scenario is 
that the best protection from challenge may incorporate a combination of strategies, such 
as a DNA prime and protein boost. Heraud, et al. found that this particular strategy 
offered the best protection from a monkeypox challenge when compared to either DNA 
or protein vaccination alone (149). While subunit vaccines have mainly focused on 
production of antibody responses, subunit smallpox vaccines expressing vaccinia virus 
immunodominant T-cell epitopes have been shown to protect mice from orthopoxvirus 
challenge (261). Thus, another strategy is to identify epitopes that are critical for T-cell 
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mediated protection from smallpox and provide these to the host immune system (262). 
Many of the current subunit vaccines under development have only been shown to 
produce short-term protection from challenge, on the order of three to four weeks after 
the last vaccine dose. Two studies have examined the ability of a subunit smallpox 
vaccine to protect long-term (3-6 months after the final vaccine dose) against lethal (and 
sublethal) challenge with vaccinia virus. These studies showed that protection against 
death was incomplete and mice developed significant to severe symptoms (110,257). 
Live vaccinia virus vaccination offers long-term immunity, on the order of decades (92) 
that likely may protect against death from smallpox (263). Subunit vaccines will likely 
not achieve this impressive benchmark, but may be improved with continued formulation 
refinement. To protect against smallpox outbreaks that may be many months or years 
apart, it may be necessary to boost individuals who were previously vaccinated with only 
a subunit vaccine. An alternative strategy might be to use subunit vaccines as a way to 
prime diverse populations to allow safer vaccination with live vaccinia virus vaccines 
(264). 
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Abstract 
 Protein-based subunit smallpox vaccines have shown their potential as effective 
alternatives to live virus vaccines in animal model challenge studies. We vaccinated mice 
with combinations of three different vaccinia virus (VACV) proteins (A33, B5, L1) and 
examined how the combined antibody responses to these proteins cooperate to effectively 
neutralize the extracellular virus (EV) infectious form of VACV. Antibodies against these 
targets were generated in the presence or absence of CpG adjuvant so that Th1-biased 
antibody responses could be compared to Th2-biased responses to the proteins with 
aluminum hydroxide alone, specifically with interest in looking at the ability of anti-B5 
and anti-A33 polyclonal antibodies (pAb) to utilize complement-mediated neutralization 
in vitro. We found that neutralization of EV by anti-A33 or anti-B5 pAb can be enhanced 
in the presence of complement if Th1-biased antibody (IgG2a) is generated. Mechanistic 
differences found for complement-mediated neutralization showed that anti-A33 
antibodies likely result in virolysis, while anti-B5 antibodies with complement can 
neutralize by opsonization (coating). In vivo studies found that mice lacking the C3 
protein of complement were less protected than wild-type mice after passive transfer of 
anti-B5 pAb or vaccination with B5. Passive transfer of anti-B5 pAb or monoclonal 
antibody into mice lacking Fc receptors (FcRs) found that FcRs were also important in 
mediating protection. These results demonstrate that both complement and FcRs are 
important effector mechanisms for antibody-mediated protection from VACV challenge 
in mice. 
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Introduction 
 In the 1970s, the World Health Organization led a successful campaign to 
eradicate smallpox using live vaccinia virus (VACV) vaccines (3). However, recent 
concern over the intentional or accidental release of variola virus has led some of the 
world’s nations to stockpile live VACV vaccines (20-22). With the risk of variola virus 
release minimal, concerns regarding live VACV vaccine’s rare but serious side effects 
and many contraindications (12,226,265) have led to the pursuit of safer smallpox 
vaccine strategies (23,266,267). Modified vaccinia virus Ankara (MVA), a highly 
attenuated VACV-derived vaccine, has been under development and will likely soon 
become a safer alternative (268,269). However, subunit vaccination is an approach that 
does not rely on production of a virus. We evaluated the efficacy and mechanism by 
which a protein-based subunit vaccine can protect against orthopoxvirus infection. 
 After vaccination, protection from orthopoxvirus disease heavily depends on 
antibody responses in animal models (100,107,109) and humans (92,93). Many of the 
responses are directed against viral surface proteins on the two virion forms, mature virus 
(MV) and extracellular virus (EV). The MV form is the most abundant virion form in 
infected cells (33) and is believed to mediate spread between hosts. The EV form 
mediates dissemination within an infected host (34,42,270,271). The MV form contains a 
large set of surface proteins, while the EV form contains an extra membrane and an 
additional, unique subset of surface proteins. Antibody against certain proteins of either 
form can be partially protective, such as L1 on MV (96,98,106,147,160) and B5 or A33 
on EV (96,98,101,109,159,168), though optimal protection is seen when antibodies are 
directed against both forms (96-98,106,110,160). Subunit protein vaccination including 
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target antigens from both forms achieves protection from lethal orthopoxvirus challenge 
in mouse and non-human primate challenge models (98,105,108,110,149). In theory, 
antibody generated against the MV form would act to neutralize a portion of the initial 
infectious dose and antibody against the EV form could then prevent some spread of 
progeny virus within a host. Having these antibody responses present at the time of 
challenge could then allow the host time to generate additional immune responses and 
provide protection from lethal disease. 
 Serum from vaccinated animals or humans is capable of efficiently neutralizing 
the MV form of VACV (98,108,110,132,272); however, direct antibody neutralization of 
the EV form has been suboptimal at even high concentrations of anti-EV antibody 
(44,109,111,113,155,159). Therefore, understanding the mechanism by which anti-EV 
antibodies provide protection has been of interest. Recent mouse studies have elucidated 
that an IgG2a isotype monoclonal antibody (mAb) against the B5 protein called B126 can 
neutralize EV in the presence of complement (C’) and utilizes C’ to partially mediate 
protection in vivo (124,125). This evidence suggests that antibody against EV would be 
more effective if it was of an isotype that mediated effector functions such as activation 
of C’ and/or Fc receptor (FcR) dependent activity (e.g. antibody dependent cellular 
cytotoxicity (ADCC)). Previous studies of antibody responses to protein vaccination 
found that formulations that included adjuvants that produced higher titers of IgG2a 
antibody in mice and IgG1 antibody in non-human primates were more effective at 
mediating protection than vaccines formulated without these adjuvants (105,108). This 
suggests that antibody with specific Fc activities might be beneficial for protection.  
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 By utilizing a high PFU luciferase reporter EV neutralization assay, we find that 
polyclonal antibody responses against the EV proteins A33 and B5 utilize C’ to 
neutralize virus in vitro, though in mechanistically different ways. These findings shed 
light on how differing viral proteins dictate the requirements for the host to neutralize 
incoming virus with C’. Additionally, we show that antibody against B5 utilizes C’ and 
FcRs to protect mice from lethal VACV challenge. These findings add to our 
understanding of how antibody can protect against orthopoxvirus disease and highlights 
the importance of understanding antibody effector functions necessary for protection to 
aid in the rational design of anti-viral vaccines and therapeutic antibodies.  
 
Materials and Methods 
Proteins and vaccine formulations 
 Proteins used in the vaccine formulations were purified recombinant baculovirus-
expressed proteins that were previously described (108) . Protein vaccines were prepared 
and used as described previously (110). Briefly, proteins (each at 2 µg/mouse) and 
adjuvant(s) were prepared in sterile PBS and a final volume of 50 µL was injected 
intramuscularly into the hind leg of ketamine/xylazine-anesthetized mice. For vaccines 
adjuvanted with alum only (Alhydrogel, Accurate Chemical, Westbury, NY), 
formulations included the alum at 200 µg aluminum ion/mouse. For vaccines formulated 
with alum and CpG, the alum was at 100 µg aluminum ion/mouse and the 
phosphorothioate B class mouse specific CpG ODN 1826 (sequence 5′-TCC ATG ACG 
TTC CTG ACG TT-3′; Coley Pharmaceutical Group, now Pfizer Inc.) was used at 50 
µg/mouse. On the day of vaccinations, vaccine formulations were prepared, mixed at 
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room temperature for 2-3 hours, and loaded into 0.3 mL insulin syringes with a 29-gauge 
needle (Becton Dickinson). 
 
Mice, immunizations, and challenge 
 BALB/c mice and C57BL/6 mice were purchased from Charles River and 
Jackson Laboratory, respectively. Fc-receptor knockout mice (FcRKO) mice on the 
BALB/c background were purchased from Taconic Farms. Complement component C3 
knockout mice (C3KO) on the C57BL/6 background (originally provided by J. D. 
Lambris, University of Pennsylvania) were bred at the University of Pennsylvania. 
Active immunizations were performed as previously described (110). Briefly, mice were 
primed by intramuscular vaccination, boosted 2 weeks later, and bled 1 day prior to 
challenge (approximately 3 weeks after the boost) to assess successful antibody 
production and isotype analysis. In some instances, additional mice were terminally bled 
prior to challenge for serum to be used in in vitro EV neutralization assays. Passive 
immunizations were performed using the anti-B5 rabbit polyclonal antibody (pAb) R182 
(96) (2 mg of purified total rabbit IgG /mouse) or the anti-B5 monoclonal antibody 
(mAb) B126 (125) (100 µg of purified mouse IgG /mouse; generously provided by 
Kyowa Hakko Kirin Co. and S. Crotty, La Jolla Institute for Allergy and Immunology). 
Antibodies, diluted in sterile saline at a final volume of 300 µL/mouse for R182 or 100 
µL/mouse for B126, were injected intraperitoneally (i.p.) one day prior to challenge. 
Control mice were given sterile saline only. Vaccinated mice were challenged as 
described previously (110). Briefly, VACV (strain WR) was grown in BSC-1 cells 
(ATCC® Number CCL-26TM) and virus from cell lysates isolated by ultracentrifugation 
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through two sequential 36% sucrose cushions. Three weeks after the boost protein 
vaccination or one day after passive immunization with antibody, mice were 
anaesthetized with ketamine/xylazine and challenged intranasally with a lethal dose of 
VACV in a total volume of 20 µL (10 µL/nostril) in sterile PBS. Challenge doses were 
confirmed by titering on BSC-1 cells the day of challenge and indicated in the figure 
legends. Mice were weighed and monitored each day and mice that reached >30% 
starting weight or met end point criteria were humanely euthanized. Experiments were 
performed under a protocol that was approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee (IACUC), Animal Welfare Assurance 
number A3079-01. To minimize pain, all viral challenges and intramuscular vaccinations 
were performed under ketamine/xylazine anesthesia. To minimize suffering after viral 
challenge, mice were monitored and humanely euthanized when end point criteria were 
met. 
 
Antibody ELISA 
 Antibody ELISA was performed as previously described (108,110). Briefly, 
plates were coated overnight at 4°C with 0.5 µg/mL non-his tagged recombinant A33, 
B5, or L1 protein in bicarbonate/carbonate coating buffer. After blocking with 5% non-
fat dry milk in PBS, 2-fold serial dilutions of mouse sera were added and incubated for 
1.5 hrs at 37°C. After washing, HRP-conjugated rabbit anti-mouse IgG (Abcam, 
Cambridge, MA) secondary antibody was added at 1:4000 in blocking buffer and 
incubated at 37°C for 1 hr. Color development was performed using ABTS substrate 
(Sigma) for 20 minutes at room temperature. The reaction was stopped using 1% SDS in 
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distilled water. IgG isotype was assessed similarly, using HRP-conjugated rat anti-mouse 
IgG1 or IgG2a (BD Biosciences Pharmingen), or HRP-conjugated goat anti-mouse IgG2c 
(SouthernBiotech, Birmingham, AL) secondary antibody diluted 1:1000, 1:1000, and 
1:4000 respectively in blocking buffer and incubated for 1 hr at 37°C. 
 
In vivo complement depletion 
 C’ was transiently depleted using native Cobra Venom Factor (CVF) from Naja 
naja kaouthia (Quidel Corporation) as previously described (125). Briefly, 10 µg (~4 
units) of CVF in sterile saline (100 µL total volume) was administered i.p to mice on 
days -1, 2, and 5 of challenge. Complement depletion was confirmed on days 0, 3, and 6 
by C3 western blotting (273), C3 ELISA (125), and CH50 assay (274,275) (Fig. 3-1). We 
found that C’ was fully depleted on days 0 and 3, but C’ activity and C3 protein were at 
~50% the levels of undepleted sera on day 6 confirming previous findings of transient 
depletion (125). Intranasal challenge was performed on day 0. 
 
EV production 
 RK-13 cells (ATCC® Number CCL-37TM) were plated in 6-well plates 2 days 
prior to use and used at 100% confluency. To produce EV, RK-13 cells were infected 
with vaccinia IHD-JvFire (276) (generously provided by B. Moss, NIH) in serum-free 
MEM at MOI of 0.5. Two days after infection, supernatant was harvested, clarified by 
centrifugation at 450 × g at 4°C, and the virus remaining in the supernatant was 
immediately titered in the presence of MV neutralizing monoclonal antibody 2D5 (1:500 
dilution of ascites fluid) (277) . In general, based on titering of supernatants in the 
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presence or absence of 2D5, >80% of virus in the supernatants was EV. Clarified media 
was stored on ice at 4°C and used within a week of isolation. For EV expressing specific 
human complement regulators, the same protocol for EV preparation and titering was 
followed except that simian virus 40-transformed aortic rat endothelial cells (SVAREC) 
stably transfected with plasmids expressing human CD55 or human CD59 were used 
(46,278) (a generous gift of G. L. Smith, Imperial College of London). We confirmed 
expression of human CD55 and human CD59 in these cell lines by western blotting using 
polyclonal rabbit anti-human CD55 and anti-human CD59 antibodies (Santa Cruz 
Biotechnology) (Fig. 3-2). The parental and stably transfected SVAREC cells were 
maintained in DMEM with 10% FBS and 100 µg/mL hygromycin B. 
 
EV neutralization in the presence of complement 
 Serum from vaccinated mice or rabbit pAb or mAb was serially diluted 1:3 in 
triplicate in serum free MEM in a round-bottom 96-well plate. Serum free MEM was 
added to all wells so that each well had 50 µL total volume. Next, ~5x104 PFU of EV 
containing a 1:500 final dilution of anti-MV mAb 2D5 in MEM was added to each well 
(22 µL/well) so that each well had a total volume of 72 µL. Baby rabbit complement (C’) 
(Cedarlane Laboratories, Burlington, NC) at a final dilution of 10% (8 µL) was added to 
each well so that the final volume in each well was 80 µL. Alternatively, heat inactivated 
baby rabbit C’ (iC’) was added as a negative control. The 96-well plates containing virus, 
antibody, and C’ were incubated at 37°C for 30 minutes after which the contents from 
each well was transferred to Costar 96-well white clear-bottom tissue culture treated 
plates (Corning) containing a monolayer of BSC-1 cells. The BSC-1 cells were prepared 
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Figure 3-1. Cobra Venom Factor (CVF) treatment of BALB/c mice transiently 
depletes complement.  
To assess the degree of C’ depletion after CVF treatment, groups of 11- to 12-week old 
female BALB/c mice (2 mice per group) were treated with CVF and then terminally bled 
the following day. One group was treated on day -1 and bled the next day (d0). A second 
group was treated on days -1 and +2 and bled the next day (d3). A third group was treated 
on days -1, +2, and +5 and bled the next day (d6). A group of untreated mice was used a 
control (No CVF). (A) CH50 assay using rabbit erythrocytes (Complement Technology, 
Tyler, TX) sensitized with goat anti-rabbit erythrocyte antibody (MP Biomedicals, Solon, 
OH) was performed with sera from mice treated or not treated with CVF. Complement 
activity levels on days 0 and 3 were low, while some complement activity returned by 
day 6. Note that sensitized rabbit erythrocytes were used because sensitized sheep 
erythrocytes are resistant to lysis by mouse complement. (B) Western blot of C3 protein 
in sera of mice treated or not treated with CVF. Serum (2 µl) from the indicated group of 
mice was loaded on to a 10% polyacrylamide gel. After blotting, HRP-conjugated goat 
anti-mouse C3 antibody (MP Biomedicals, Solon, OH) at 1:10,000 was used to probe for 
the presence of C3. C3 protein was not detected on days 0 and 3, while some C3 protein 
was detected on day 6. 
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Figure 3-2. CD55 and CD59 are detected in stably transfected SVAREC cell 
lines.  
SVAREC cell lines stably transfected to express CD55 and CD59 (46,278) were grown 
under selective pressure as described in materials and methods. Western blotting for 
either CD55 (αCD55) or CD59 (αCD55) was performed on lysates from the parental 
SVAREC cell line expressing no human complement regulators (Par), a SVAREC cell 
line expressing CD55 (CD55), and a SVAREC cell line expressing CD59 (CD59). Rabbit 
polyclonal anti-human CD55 and anti-human CD59 antibodies were used at a dilution of 
1:250. CD55 was only detected in the CD55-expressing cell line at its expected size of 
~70kDa and CD59 was only detected in the CD59-expressing cell line at its expected size 
of ~20kDa. 
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on these plates 48 hours before use and subsequently used at 100% confluency. Once 
infected, the plates were incubated at 37°C for ~20 hours. Luciferase production was 
measured by adding 100 µL of SuperLight™ Luciferase Reporter Gene Assay Reagent 
(BioAssay Systems, Hayward, Ca) directly to each well and relative light unit (RLU) 
measurements obtained on a MLX Revelation microtiter plate luminometer (Dynex 
Technologies). To relate RLU readings to PFU, known amounts of EV were serially 
diluted on the same BSC-1 plate to generate a standard curve. Linear fit was calculated 
and RLU readings were converted to PFU. 
 Neutralization of EV with human C’ (Sigma-Aldrich, St. Louis, MO) or human 
C’ depleted of C1q (Complement Technology, Tyler, TX) or C5 (Sigma-Aldrich, St. 
Louis, MO) was performed using the same luciferase assay as above with the following 
modifications. Prior to the addition of C’, virus and antibody were incubated for 1 hour. 
After the addition of human C’ (used at a concentration of 20%), the plate was incubated 
for an additional 1 hr. These changes were made because we found that neutralization 
using human C’ with the rabbit and mouse antibodies was less efficient than with baby 
rabbit C’. Percent neutralization was calculated by dividing luciferase RLU readings from 
wells containing antibody by RLU readings of control wells containing no antibody for 
each serially diluted antibody. Percent neutralization by virolysis was calculated by the 
following formula: 100 – [(%NAb – %NAb with C5defC’)/(%NAb – %NAb with 
hC’)*100] where %NAb is percent neutralization with antibody, C5defC’ is C5 deficient 
human C’ and hC’ is complete human C’. This formula controls for any neutralization 
with antibody alone and determines the contribution of the lytic pathway. 
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Statistics 
 Statistical significance was determined using Prism 5.0 software. Differences in 
percent neutralization and weight loss were calculated using an unpaired 2-tailed t-test. 
Differences in survival were calculated using Kaplan-Meier analysis and log-rank test. P 
values of less than 0.05 were considered significant. 
 
Results 
Protection from lethal VACV challenge requires the inclusion of CpG adjuvant and 
correlates with the induction of IgG2a antibody. 
 We have previously shown that vaccinating mice and non-human primates with a 
combination of VACV proteins and CpG and aluminum hydroxide (alum) protects from a 
lethal poxvirus infection (108,110). Using different adjuvant systems (MPL+TDM or 
QS21), Fogg et al. showed that vaccination with combinations of proteins provided better 
protection than individual proteins (98). Here, we investigated the protection of BALB/c 
mice vaccinated with both combination and individual proteins with adjuvants CpG/alum 
or alum alone (Table 2-1). Mice that received a vaccine adjuvanted only with alum 
succumbed to infection, regardless of the combination of proteins given. Mice receiving 
protein(s) with CpG/alum were able to survive infection to varying degrees, with 
combination proteins achieving 100 percent survival. The combination protein vaccines 
achieved 100 percent protection due to antibody generated against both MV and EV. 
L1/CpG/alum and B5/CpG/alum showed partial protection. Notably, while 
A33/CpG/alum showed no survival at this challenge dose, the addition of A33 to 
L1/CpG/alum resulted in less post-challenge weight loss than mice vaccinated with only  
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Table 3-1. Summary of survival and maximum weight loss after challenge with 4x106 pfu 
VACV 
Vaccination groupa Percent survival 
Maximum percent 
average weight lossb 
ABL/CpG/alum 100 10 
AL/CpG/alum 100 2 
BL/CpG/alum 100 12 
L1/CpG/alum 80 23 
B5/CpG/alum 40 24 
A33/CpG/alum 0 N/A 
ABL/alum 0 N/A 
AL/alum 0 N/A 
BL/alum 0 N/A 
L1/alum 0 N/A 
B5/alum 0 N/A 
A33/alum 0 N/A 
unvaccinated 0 N/A 
a. A, B, L: A33, B5, L1, respectively. Alum: aluminum hydroxide 
b. N/A: not applicable. Since these groups had 0% survival, average weight loss of the group is not reported 
since mice were sacrificed when they had 30% weight loss or died prior to reaching this degree of weight 
loss. 
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L1/CpG/alum (2% vs. 23% weight loss; p=0.0003) again demonstrating that 
combinations of proteins provided better protection than individual proteins. 
 Others have previously shown that the addition of CpG adjuvant biases the 
immune response towards Th1 in mice (105,279-282). As expected, IgG2a antibody was 
only produced in BALB/c mice given the CpG/alum combination adjuvant (Fig. 3-3). 
IgG1 was produced in both CpG/alum and alum only groups, with varying titers to the 
individual proteins. 
 
Sera from mice vaccinated with A33 or B5 /CpG/alum can neutralize large numbers of 
EV particles in the presence of complement. 
 Given the correlation seen between the appearance of Th1-biased antibodies 
(IgG2a in mice) and protection, as well as previous studies showing that Th1-biased 
antibodies are more protective than Th2-biased antibodies and can neutralize EV in the 
presence of C’ (105,108,124,125), we next determined if sera from vaccinated mice could 
neutralize EV in the presence of C’. Previously, plaque reduction assays with small 
numbers of EV (~50-150 PFU) were used to show neutralization; however, we wished to 
test the ability of antibody and C’ to neutralize large numbers of EV particles that are 
more likely present during an infection. To do this, we developed an EV neutralization 
assay with a recombinant VACV that expressed a luciferase reporter protein. For this 
assay we generated standard curves with known amounts of EV, which allowed for 
conversion of RLU to PFU. In this assay, anti-L1 mAb 2D5 (277) was always added to 
neutralize contaminating MV in the EV preparation. To confirm the functionality of this 
assay, we tested B126, an anti-B5 mAb with IgG2a isotype previously shown to  
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Figure 3-3. Antibody isotypes produced in BALB/c mice after vaccination. 
Groups of 6-week old female BALB/c mice (9 mice/group) vaccinated individually with 
A33, B5, or L1 adjuvanted with alum +/- CpG were bled three weeks after the boost 
vaccination. Equal volumes of heat-inactivated serum from individual mice in each group 
were pooled. Shown are reciprocal end-point dilutions for antibody isotypes IgG1 (white 
bars) and IgG2a (black bars) as measured by ELISA reactivity with proteins A33, B5, or 
L1. Vaccinations without CpG produced no detectable IgG2a response. 
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neutralize EV in the presence of C’ (125), as well as VMC-30, an anti-B5 mAb from a 
previously characterized panel of anti-B5 mAbs (166). As shown in Fig. 3-4, B126 was 
capable of neutralizing 97% of >104 EV particles in the presence of C’; however, VMC-
30 was not. Neutralization was abrogated if C’ was first heat inactivated. 
 Using this luciferase-based high EV particle neutralization assay, we found that 
anti-A33 and anti-B5 sera from mice vaccinated with protein and CpG/alum could 
neutralize large numbers of EV particles in the presence of C’ (Fig. 3-5). Neutralization 
was largely abrogated if C’ was first heat inactivated. Anti-B5 sera was better at C’-
mediated neutralization than anti-A33 sera, though this might be explained by the higher 
titer of IgG2a anti-B5 antibody compared to anti-A33 antibody (Fig. 3-3). Interestingly, 
while anti-A33 antibodies have the ability to neutralize EV in the presence of C’, there 
was a lack of protection in mice vaccinated with A33/CpG/alum. 
 
Anti-A33 C’-mediated antibody neutralization requires steps that could lead to EV 
outer envelope lysis, while anti-B5 C’-mediated antibody neutralization can occur by 
opsonization. 
 To elucidate why the A33/CpG/alum vaccination was not as effective as 
B5/CpG/alum at protecting mice from lethal challenge despite neutralizing EV in the 
presence of C’, we asked whether the pathway of C’-mediated neutralization was playing 
a role. Lustig, et al. demonstrated that anti-A33 polyclonal rabbit sera (pAb) resulted in 
C’-mediated lysis of the outer membrane of EV allowing anti-MV neutralizing antibody 
access to the MV particle within (97). Benhnia et al. showed that anti-B5 mouse mAb 
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Figure 3-4. Neutralization of large numbers of EV particles using anti-B5 mAbs 
and complement.  
Anti-B5 mAb B126 (squares) and anti-B5 mAb VMC-30 (circles) were used in a 
luciferase-based high PFU EV neutralization assay. ~5x104 pfu of EV was incubated with 
increasing concentrations of mAb in the presence of 10% baby rabbit C’ (solid symbols) 
or heat inactivated baby rabbit C’ (iC’) (open symbols). Luciferase units were converted 
to PFU by linear regression of a standard curve using known numbers of EV. 
Neutralization was performed in triplicate for C’ and duplicate for iC’ and represents two 
independent experiments. Error bars represent standard deviation. 
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Figure 3-5. Neutralization of large numbers of EV particles using sera from mice 
vaccinated with A33 or B5 in CpG/alum or alum only.  
Sera from BALB/c mice vaccinated with A33 (A) or B5 (B) adjuvanted with CpG/alum 
(squares) or alum only (circles) were collected 3 weeks post boost vaccination. Equal 
volumes of heat-inactivated serum from groups of mice were pooled (9 mice/group). 
~5x104 pfu of EV was neutralized with increasing amounts of sera in the presence of 
10% baby rabbit C’ (closed symbols) or heat inactivated baby rabbit C’ (iC’) (open 
symbols). Luciferase units were converted to PFU by linear regression of a standard 
curve using known numbers of EV. Neutralization was performed in triplicate for C’ and 
duplicate for iC’ and represents three independent experiments. Error bars represent 
standard deviation.  
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B126 neutralized EV by opsonizing particles with complement and could neutralize in 
the absence of membrane attack complex formation and without an anti-MV antibody 
present (125). However, the question remained whether these observations with anti-A33 
and anti-B5 antibodies were due to the differing EV target proteins or if the differences in 
C’-mediated neutralization was due to inherent differences in the two studies (e.g., pAb 
vs. mAb, rabbit vs. mouse antibodies, and different adjuvants used during generation of 
the antibodies). To determine if different C’-mediated neutralization pathways might be 
used for different EV protein targets, sera from mice vaccinated with either A33 or B5 
/CpG/alum were used with human C’ depleted of C5 or C1q (Figs. 3-6A-C). Depletion of 
either C1q or C5 from sera significantly reduced the ability of anti-A33 mouse sera to 
efficiently neutralize EV (Fig. 3-6A) indicating that steps that lead to formation of the 
membrane attack complex were required for neutralization. However, only the sera 
depleted of C1q affected the ability of anti-B5 mouse sera to neutralize EV (Fig. 3-6B) 
indicating that membrane attack complex does not need to form for successful EV 
neutralization. Similar results were obtained when rabbit pAb against A33 and B5 was 
used (Figs. 3-6D and E). These results are consistent with the previously described 
findings that the mechanism of C’-mediated neutralization for A33 and B5 
differ(97,125), with anti-A33 antibody relying on virolysis and anti-B5 antibody able to 
neutralize by opsonization (Figs. 3-6C and F). 
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Figure 3-6. Contribution of steps leading to the formation of the membrane 
attack complex in complement-mediated neutralization of EV.  
Graphed is the percent neutralization of EV in the presence of antibody and 20% human 
C’ or with human C’ depleted of component C5 or C1q. Sera from BALB/c mice 
vaccinated with A33 or B5/CpG/alum was used at a dilution of 1:20 (A-C). Rabbit pAb 
against A33 and B5 was used at 50 µg/mL (D-F). Data shown in A, B, D, and E are 
percent neutralization of no antibody control. Data in C and F show the specific EV 
neutralization dependent on C5 (virolysis) and was calculated as described in materials 
and methods. Neutralizations were performed in triplicate. Error bars represent standard 
deviation. * p<0.05. 
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(The following paragraph and figure are unpublished.)  
 The inability of anti-A33 antibody to neutralize EV in the presence of C5 depleted 
sera suggested that C’ activation steps downstream of C5 were needed; however, the 
possibility remained that a C5-dependent, MAC-independent mechanism of 
neutralization was being utilized by anti-A33 antibody and complete C’. Such a 
mechanism has been reported for C’-mediated neutralization of HSV (194). To confirm 
that MAC formation was required, we measured the ability polyclonal rabbit antibody 
against A33 to neutralize EV in the presence of human C’ depleted of C8. In the presence 
of complete human C’, anti-A33 antibody was able to neutralize EV, but not in the 
presence of C5, C8, or C1q depleted human C’ (Fig. 3-7). The percent neutralization by 
virolysis dependent on C8 was calculated as described in materials and methods using C8 
instead of C5 and found to be 93.9%. This finding confirms that C’ activation steps 
downstream of C5 and C8, likely formation of the MAC, are needed for neutralization of 
EV in the presence of C’.  
 Benhnia hypothesized that antibody alone was unable to fulfill the basic 
occupancy model for EV neutralization because of the amount of B5 protein on the EV 
surface and that antibody-induced C’ coating of the EV membrane allowed for the 
occupancy model to succeed (124). To examine this further, we varied the anti-B5 
antibody concentration as well as used EV that incorporated different C’ regulators into 
its outer envelope. These C’ regulators (CD55 and CD59) have been shown to be present 
on the EV envelope (46). CD55, also known as decay-accelerating factor, inhibits stable 
formation of the C3 convertase and down-modulates the amount of C3b/C4b deposition 
as well as the downstream steps in the C’ cascade (199) and thus could alter the ability of 
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Figure 3-7. Contribution of complement component C8 in complement-mediated 
neutralization of EV.  
Graphed is the percent neutralization of EV in the presence of antibody and 20% human 
C’ or with human C’ depleted of component C5, C8, or C1q. Rabbit pAb against A33 
was used at 50 µg/mL. Data shown is percent neutralization of no antibody control. 
Neutralizations were performed in triplicate. Error bars represent standard deviation. * 
p<0.05. (Unpublished) 
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C’ to opsonize EV. CD59, or protectin, prevents formation of the membrane attack 
complex and could block virolysis of the EV membrane. We produced EV that had each 
C’ regulator on its surface using previously described SVAREC cell lines that expressed 
no human C’ regulators or were stably transfected to express human CD55 or 
CD59(46,278). At high concentrations of anti-B5 sera (1:80), EV produced in the cell 
line expressing CD55 showed some protection from C’-mediated neutralization (Fig. 3-8, 
striped bar), while EV produced in the cell line expressing CD59 showed no protection 
from C’-mediated neutralization (Fig. 3-8, white bar). This data supports a model where 
virolysis is not needed since the presence of CD59 did not alter the ability to neutralize 
EV at the relatively high concentration of antibody. However, at relatively low 
concentrations of anti-B5 sera (1:640), EV produced in the cell lines expressing CD55 or 
CD59 were equally protected from C’-mediated neutralization (striped and white bars). 
The finding that CD59 provides protection equal to that of CD55 when antibody is at low 
concentration indicates that virolysis becomes the predominant pathway for 
neutralization. Therefore, if the amount of antibody on the surface of EV is limited, 
virolysis is required for neutralization as was seen with anti-A33 sera. 
 
Complement is partially responsible for the protection seen in mice after passive or 
active immunization. 
 To determine what effector functions of antibody were important for in vivo 
protection, we used immunizations that targeted B5. Benhnia et al. found that passive 
immunization with mAb B126 was less protective in vivo if mice were first transiently 
depleted of C’ using cobra venom factor (CVF) (125). However, mice still recovered and  
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Figure 3-8. Protection of EV by human regulators of complement from 
complement-mediated neutralization at high and low amounts of antibody.  
Sera from BALB/c mice vaccinated with B5/CpG/alum was used to neutralize EV 
produced in SVAREC cells expressing CD55 (striped bars), CD59 (white bars), or no 
human regulators of C’ (black bars) in the presence of 20% human C’. While a full range 
of antibody dilutions were tested, shown is a representative low dilution (1/80) and high 
dilution (1/640) of antibody and the effect on complement-mediated neutralization of EV 
containing CD55 or CD59. The full range of antibody dilutions revealed that EV was 
partially protected by CD59 at dilutions between 1/80 and 1/640, but not as protective as 
CD55 at those dilutions. Data is shown as percent neutralization of no antibody control. 
Error bars represent standard deviation. * p<0.05. 
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were more protected than naïve mice. To first confirm the contribution of C’ in protection 
by a polyclonal anti-B5 antibody response, we passively transferred pAb rabbit anti-B5 
antibody (R182) into C3 knockout (C3KO) and wild-type mice (C57BL/6) and 
intranasally (i.n.) challenged them with a lethal dose of VACV (Fig. 3-9). C3KO mice 
lost significantly more weight than C57BL/6 mice indicating that C’ contributed to 
protection. However, similar to Benhnia et al. (125), when compared to the controls that 
were not treated with antibody, we did note partial protection in the absence of C’. Next, 
to determine if antibodies produced during active immunization protected in a similar 
fashion, we vaccinated C3KO and wild-type C57BL/6 mice with B5/CpG/alum. 
Interestingly, despite a few reports that C3KO mice were defective in making antibody 
responses (273,283-285), we found that our vaccine resulted in total IgG and IgG2c 
responses comparable to the wild type C57BL/6 mice (Fig. 3-10A). After vaccinations, 
mice were challenged i.n. with VACV and weight loss was monitored. Vaccinated 
C57BL/6 mice lost minimal weight and fully recovered by day 8 post-infection. 
Conversely, vaccinated C3KO mice lost significant weight similar to C57BL/6 naïve and 
C3KO naïve mice (Fig. 3-10B) again indicating a role of C’ in protection from challenge. 
 
Fc receptors protect mice passively transferred with anti-B5 antibody in the absence of 
complement. 
 In the work by Benhnia, et al (125), it was unclear whether the recovery of normal 
levels of C’ after CVF depletion or effector functions mediated through Fc receptors 
(FcRs) were responsible for the protection afforded by mAb B126 even after C’ 
depletion. Based on our findings in C3KO mice, it was evident that additional  
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Figure 3-9. Protection from vaccinia virus challenge by anti-B5 rabbit pAb in 
C57BL/6 and C3KO mice.  
Anti-B5 rabbit pAb (R182; 2 mg/mouse) were passively transferred by the i.p. route into 
9-week old female C57BL/6 (circles) and C3KO (squares) mice. Groups of mice that did 
not receive antibody treatment were included (dashed lines and open symbols). Twenty-
four hours after antibody treatment, mice were i.n. challenged with ~9x104 pfu of 
vaccinia virus. Weight loss was monitored and the percent weight loss calculated against 
each mouse’s starting weight. Five of 5 mice in each R182 treated group survived 
challenge while 4 of 4 naïve C57BL/6 and 3 of 4 naïve C3KO mice did not. Error bars 
represent standard error. * p<0.05. 
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Figure 3-10. Protection from vaccinia virus challenge by B5/CpG/alum 
vaccination in C57BL/6 and C3KO mice.  
9-week old male C57BL/6 (circles) (5/group) and C3KO (squares) (6/group) mice were 
vaccinated with B5/CpG/alum. (A) Anti-B5 total IgG and IgG2c were measured by 
ELISA from sera taken from vaccinated mice 3 weeks after boost vaccination. Because 
C57BL/6 mice do not have the gene for IgG2a, IgG2c was measured and is known to 
have similar effector functions (284,286,287). (B) Three weeks after the boost 
vaccination, mice were i.n. challenged with ~2x105 pfu of vaccinia virus. Unvaccinated 
naïve C57BL/6 and C3KO groups were included (3 mice/group) (dashed lines and open 
symbols). Weight loss was monitored and the percent weight loss calculated against each 
mouse’s starting weight. One of the B5/CpG/alum vaccinated C57BL/6 mice lost 
significantly more weight than the other 4 mice in its group and was removed from 
analysis based on Grubbs’ test for outlier detection. Error bars represent standard error. 
Data shown is representative of two independent experiments. * p<0.05. At time of 
challenge, the mice were ~14 weeks old and at this challenge dose in the C57BL/6 
background only about half of the unvaccinated mice required euthanasia. Thus, 
mortality between groups was not statistically significant. 
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mechanisms were playing a role in protecting mice in the absence of C’. Thus, we 
passively transferred FcRKO mice with anti-B5 pAb (R182) and i.n. challenged them 
with a lethal dose of VACV (Fig. 3-11). These mice lost significant weight (~25%) but 
all survived challenge. However, if FcRKO mice were transiently depleted of C’ with 
CVF before challenge, all mice succumbed to infection indicating that both FcR and C’ 
play a role in protection (Fig. 3-11B). Given the finding that FcRs play a role in 
protection with rabbit polyclonal anti-B5 antibody, we sought to determine if mAb B126 
also used FcRs to protect mice from lethal challenge. B126 was passively transferred into 
FcRKO or wild type BALB/c mice followed by i.n. challenge with a lethal dose of 
VACV (Fig. 3-12). By day 6, significant differences were seen in the weight loss of these 
BALB/c and FcRKO mice treated with B126. By day 8, B126 treated FcRKO mice had 
succumbed to infection while the wild type BALB/c mice that received B126 had already 
started to recover and ultimately survived challenge again indicating an important role for 
FcRs in protection after passive immunization.  
 
Discussion 
 Vaccine induced antibodies have been shown to be critical for protection from 
orthopoxvirus challenge (103,107,245,288). Likewise, protection afforded by protein 
vaccination is thought to heavily depend on antibody responses generated and often these 
responses are measured and reported as a possible correlate of protection 
(98,101,105,108-110,168). However, besides direct pathogen neutralization, these 
antibody responses could protect through various effector mechanisms such as activation 
of C’ to neutralize virus or lyse infected cells and activating cellular responses through  
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Figure 3-11. Protection from vaccinia virus challenge by anti-B5 rabbit pAb in 
FcRKO mice.  
Anti-B5 rabbit pAb (R182; 2 mg/mouse) were passively transferred by the i.p. route into 
7- to 13-week old female FcRKO mice (8 mice/group; circles). Approximately 4 units of 
cobra venom factor were delivered on days -1, 2, and 5 by the i.p. route to one group of 
mice that received R182 (open circles). A group FcRKO mice that did not receive 
antibody or CVF was included (crosses). Twenty-four hours after antibody treatment, 
mice were i.n. challenged with ~3x105 pfu of vaccinia virus. (A) Survival differences 
between the FcRKO mice treated with R182 and those treated with R182 and CVF were 
statistically significant; p=0.0084 (Log-rank Test). (B) Weight loss was monitored and 
percent weight loss calculated against each mouse’s starting weight. Error bars represent 
standard error. Data shown is representative of two independent experiments. 
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Figure 3-12. Protection from vaccinia virus challenge by anti-B5 mAb B126 is 
FcR dependent.  
Anti-B5 mAb (B126; 100 µg) was passively transferred by the i.p. route into 8- to 9-week 
old female FcRKO (closed circle) and 8-week old female BALB/c mice (closed squares) 
(4 mice/group). A naïve female BALB/c control group was included (dashed line, open 
square). Twenty-four hours after antibody treatment, mice were i.n. challenged with 
~4x105 pfu of vaccinia virus. Weight loss was monitored and percent weight loss 
calculated against each mouse’s starting weight. Error bars represent standard error. Data 
shown is representative of two independent experiments. * p<0.05. All BALB/c mice 
given B126 survived challenge, while FcRKO mice given B126 and untreated BALB/c 
mice all succumbed to infection and/or reached end-point criteria for euthanasia. 
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FcRs to lyse and kill infected cells. Here, we examined the functionality of antibody 
responses generated after vaccination with individual VACV proteins to better 
understand the type of antibody response needed to confer protection. Recently, Benhnia 
et al. showed that a mouse anti-B5 mAb named B126 required C’ to neutralize VACV 
EV and mediate in vivo protection (125). Therefore, we examined whether the same was 
true for pAb responses after active or passive immunization against the VACV EV 
protein B5.  
 To do this, we initially set up a new luciferase based assay to measure the 
neutralization of large numbers of EV particles. B126 was confirmed to neutralize EV in 
the presence of C’ (Fig. 3-4) as had been previously reported (125). We also tested 
another anti-B5 mAb (VMC-30; (166)) and found that it was unable to neutralize EV in 
the presence of C’ (Fig. 3-4). Benhnia et al, reported that B126 was an IgG2a isotype and 
this afforded it the ability to activate C’ as mAbs of IgG1 isotype did not (125). 
Interestingly, VMC-30 is an IgG2b isotype (166), which should also be capable of 
activating C’ and other effector functions similar to IgG2a (186-188,208). However, in 
this case, the isotype of the mAb did not predict functional activity in vitro and therefore 
highlights the importance of testing functional activity of mAb and not relying solely on 
the prediction of isotype analysis. When passively transferred into mice, VMC-30 also 
did not protect against challenge (data not shown), again demonstrating the need for 
effector function for protection in vivo. We confirmed the isotype of VMC-30 and 
speculate that it may have been unable to neutralize VACV in the presence of C’ due to 
potential amino acid changes in the Fc region of the mAb which could abrogate 
functional activity (170,174). However the IgG2b isotype could interact with Fc 
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receptors, so other factors like affinity may be playing a role in its inability to protect. 
The role of IgG2b in mediating protection from vaccinia virus infections in vivo is 
currently unknown. This may be interesting to examine further in the future. 
 As others had previously found in BALB/c mice (105), we observed that 
protection in vivo by protein vaccination was correlated with the production of IgG2a 
antibodies (Table 3-1 and Fig. 3-3). Therefore, we predicted that these antibodies would 
neutralize EV in the presence of C’ similar to B126, but we needed to fully examine this 
given the lack of C’-fixing activity with mAb VMC-30. We found that sera containing 
IgG2a from mice vaccinated with A33 or B5/CpG/alum could utilize C’ to neutralize 
large numbers of EV particles in vitro. Sera lacking IgG2a antibody from mice 
vaccinated with proteins and alum only was unable to neutralize virus in the presence of 
C’ (Fig. 3-5). This confirms the importance of isotype and strengthens the correlation 
between protection of mice and production of IgG2a isotype antibodies. 
 Further examination of the mechanism of C’-mediated neutralization revealed that 
anti-A33 and anti-B5 antibody responses utilized C’ to neutralize EV in different ways 
(Fig. 3-6). In agreement with previous reports (97,124,125) , A33 antibody required C’ 
activation steps that could lead to virolysis, while B5 antibody and C’ could neutralize 
through opsonization. Benhnia et al. provided a model of anti-B5 antibody- C’ mediated 
neutralization whereby B5 protein was not in high enough density on the surface of EV to 
allow for the basic occupancy model of antibody neutralization to succeed (124,125). 
They reasoned that deposited C’ components enhanced the footprint of antibody bound to 
B5 protein on the virus surface to assist in neutralization. This model explained why 
virolysis was not needed. Lustig et al. provided a model of C’ assisted EV neutralization 
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for anti-A33 antibody (97). In this model, C’ lyses the outer envelope of EV, which 
provides anti-MV antibody access to the MV virion within. An anti-MV antibody was 
required to be present during the assay for C’ assisted neutralization to occur. Because 
our luciferase based EV neutralization assay always contains an anti-MV antibody to 
eliminate contaminating MV in the EV preparations, we were unable to examine 
neutralization in the absence of an anti-MV antibody. Despite this, our data suggests that 
both mechanisms are correct for each protein target and not due to differences in antibody 
species, clonality, or adjuvant used to generate the antibody. 
 We hypothesized that disparity in A33 and B5 protein density on the EV surface 
contributed to the difference in mechanism. Galmiche et al. showed that total EV lysate 
had A33 and B5 protein amounts of <5 µg/mg and 30 µg/mg, respectively (109). The 
reduced amount of A33 protein on the EV surface could decrease the amount of antibody 
bound to EV to the point where coating with C1q and C3b/C4b in the area around the 
bound antibody is still insufficient to completely opsonize the EV virion. Under this 
scenario, formation of even one or two membrane attack complexes (MAC) on the EV 
virion could be enough to disrupt the outer membrane and allow access of neutralizing 
MV antibody. This model would predict that further limiting the amount of anti-B5 
antibody bound to the EV surface (equivalent to a lower density of protein) would switch 
the mechanism of C’-mediated neutralization from opsonization to lysis. To test this 
hypothesis, we used a novel approach whereby EV was generated with the incorporation 
of different human regulators of C’ (Fig. 3-8). We found that when EV was generated in 
cells that would result in the inclusion of CD59 (an inhibitor of MAC formation) on EV, 
CD59 could not provide additional protection from C’-mediated neutralization at high 
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concentrations of anti-B5 antibody as neutralization could occur through opsonization. 
However, at low concentrations of anti-B5 antibody, CD59 was protective against C’-
mediated neutralization to the same degree as EV containing CD55 (an inhibitor of C3 
convertase formation), likely indicating the mechanistic switch from opsonization to 
lysis. Additionally, we found that under the right experimental conditions, human 
regulators of C’ on the VACV EV surface can block C’ activation by antibody, and not 
just activation by C’ alone (46). These findings provide new insight into interactions of 
antibody, C’, and viral protein and how those interactions impact neutralization of virus.  
 The finding that A33 requires virolysis for C’-mediated neutralization while B5 
does not may also explain differences in protection we observed after vaccinating with 
A33 or B5/CpG/alum. At the challenge doses we used, the ability of B5 to provide at 
least partial protection could be explained by the ability to neutralize EV in the absence 
of an anti-MV antibody response, which A33 is incapable. A33 antibody and C’ would 
simply release MV particles which could propagate the infection, albeit that some anti-
A33 effect could be gained by allowing C’ free access to the C’ sensitive MV particle or 
A33 antibody-dependent lysis of infected cells. This may also explain why a vaccine that 
adds L1 to A33 improves protection from disease compared to A33 or L1 alone (Table 3-
1). 
 To examine more closely which effector functions of antibodies are important for 
protection in vivo, we studied the role of C’ and FcRs in the protection we observed with 
B5 antibody. The rabbit anti-B5 pAb used in neutralization experiments had been 
previously shown to be protective in vivo by passive immunization (96) and the ability to 
neutralize EV in the presence of C’ potentially contributed to this observation. To 
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confirm this, we examined the ability of anti-B5 antibody to protect mice in the absence 
of the central C’ component C3 (Figs. 3-9 and 3-10). We found that both passive 
immunization with rabbit anti-B5 antibody and active immunization with B5/CpG/alum 
partially relied on C’ for protection. Similar to previously reported studies that transiently 
depleted C’ in challenged animals (125,289), we found that antibody could still provide 
partial protection even in the genetic absence of C3, which abrogates the function of the 
C’ system (Figs. 3-9 and 3-10B). Somewhat unexpectedly, we found that vaccinated 
C3KO mice generated antibody responses similar to that of wild-type mice (Fig. 3-10A). 
Binding of the B cell antigen receptor/co-receptor by C3d-antigen complexes lowers the 
threshold for B cell activation by 10- to 100-fold (290) and provides an important 
survival signal to B cells (291). CpG has been shown to directly stimulate B cells and 
enhance IgG secretion (292,293). Inclusion of CpG in our vaccine may stimulate B-cells 
in a way that overcomes the requirement of C’ activation for B-cell priming, activation, 
and survival.  
 Because we observed partial protection in the absence of C’, we examined 
whether FcRs may be playing a role in protection as was previously suggested by 
Benhnia et al. (125). FcRKO mice were partially protected by passive transfer of rabbit 
anti-B5 pAB, but not if C’ was transiently depleted with CVF first (Fig. 3-11). Likewise, 
anti-B5 mAb B126 was heavily reliant on FcRs for its protective effects (Fig. 3-12). This 
finding indicates that both C’ and FcRs can contribute to protection and that both are 
important effector functions that mediate protection by pAb anti-B5 responses in vivo.  
 In summary, we found that after active vaccination, pAb responses against the EV 
form of VACV utilize C’ and FcRs to mediate protection. C’ plays an important role in 
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neutralization and the protein target can alter the mechanism through which this 
neutralization occurs. FcRs contribute to protection in vivo likely through Fc mediated 
phagocytosis and/or ADCC. Together these effector functions cooperate to provide 
protection from challenge. Importantly, we suggest the need to evaluate antibody effector 
function requirements for protection in vivo to any pathogen, especially if monoclonal 
antibodies are to be used. Advances in the understanding of the molecular basis for 
effector functions of antibody allows for customization. By altering the Fc region amino 
acid sequence one can impart or abrogate specific effector functions (170). By 
understanding the mechanism by which antibodies provide protection against a given 
pathogen and understanding how to manipulate antibody effector functions, vaccines and 
other therapeutic antibodies can be designed to specifications that activate C’ or FcRs as 
necessary.  
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Abstract 
Concerns about infections caused by orthopoxviruses, such as variola and 
monkeypox viruses, drive ongoing efforts to develop novel smallpox vaccines that are 
both effective and safe to use in diverse populations. A subunit smallpox vaccine 
comprising vaccinia virus membrane proteins A33, B5, L1, A27 and aluminum 
hydroxide (alum) ± CpG were administered to non-human primates, which were 
subsequently challenged with a lethal intravenous dose of monkeypox virus. Alum-
adjuvanted vaccines provided only partial protection but the addition of CpG provided 
full protection that was associated with a more homogeneous antibody response and 
stronger IgG1 responses. These results indicate that it is feasible to develop a highly 
effective subunit vaccine against orthopoxvirus infections as a safer alternative to live 
vaccinia virus vaccination. 
 
Introduction 
Smallpox was eradicated worldwide by a 1970s campaign led by the World 
Health Organization (3). However the possibility of accidental or purposeful re-
introduction of variola virus has led governments to stockpile live vaccinia virus (VACV) 
vaccines like ACAM2000™ derived from the Dryvax® vaccine (223,224). Serious side 
effects can accompany live vaccinia-based vaccines, especially in immunocompromised 
people and those with common skin diseases. This has encouraged efforts to develop 
safer smallpox vaccines (216-219). Modified vaccinia Ankara (MVA), a highly 
attenuated smallpox vaccine under development (268), may be safer, but requires high 
doses. Zoonotic human infections with monkeypox virus (MPXV) in the USA (6) further 
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illustrate the need for safe and effective vaccines against other poxviruses. Our approach 
has been to develop and test the efficacy of a subunit protein-based vaccine. 
Identification of target antigens for a subunit vaccine is challenging because 
poxviruses encode hundreds of proteins and their complex life cycle produce two 
infectious forms: mature virus (MV) and extracellular virus (EV) (33,34). MV is an 
enveloped virus with many surface proteins required for infectivity (33). EV has an 
additional membrane surrounding the MV particle with another set of unique membrane 
proteins (33,34). Both forms are important in viral acquisition and spread. Subunit 
vaccines under development usually contain antigens from both envelopes 
(98,105,106,110,138,149,153,160,246,255,256,294). Here we report that vaccination of 
non-human primates (NHP) with purified protein ectodomains of A33 and B5 derived 
from EV plus L1 and A27 derived from MV, combined with the adjuvants Alhydrogel 
and CpG, provided full protection of NHPs from lethal intravenous challenge with 
MPXV. Our results clearly show the feasibility of developing safe and effective subunit 
vaccines for human use against smallpox and monkeypox. 
 
Materials and Methods 
Non-human primates 
Two separate NHP vaccination and challenge studies were performed in 
cynomolgus macaques (Macaca fascicularis) with three- or two-dose regimens. The 3-
dose study involved 30 macaques (16 females, 14 males) obtained from Three Spring 
Scientific (Perkasie, PA) then vaccinated and challenged at Southern Research Institute 
(SRI, Frederick, MD). The 2-dose study involved 12 macaques (7 females, 5 males) 
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obtained from Charles River Laboratories (Reno, NV), quarantined (3 months) and 
vaccinated at University of Maryland School of Medicine (Baltimore, MD) then 
challenged at SRI. All animal facilities are approved by the Association for the 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) International and 
procedures were in accordance with relevant federal policies and guidelines, and 
protocols were approved by Institutional Animal Care and Use Committees. 
 
VACV proteins  
For this study, recombinant proteins were produced by infecting whole insect 
larvae with recombinant baculoviruses (details in a manuscript in preparation). Briefly, 
recombinant A33, B5, L1, and A27 (145,166,167) were produced by infecting insect 
larvae (cabbage looper moth, Trichoplusia ni) (295,296) with recombinant baculoviruses 
(Autographa californica multiple nuclear polyhedrosis virus) expressing individual 
histidine-tagged VACV proteins. After metal affinity chromatography, additional ion 
exchange polishing and formulation chromatographic steps were added to ensure very 
high purity proteins (>98% by digitized Coomassie image analysis) that were largely free 
of contaminating host proteins / proteases. The protein preparations were verified to have 
endotoxin levels below FDA guidance levels. 
 
Vaccinations 
Vaccines comprised three or four antigens (20 or 100 µg each) adsorbed to aluminum 
hydroxide at 8.25 or 16.5 µg aluminum ion/µg protein (Alhydrogel, Accurate Chemical 
& Scientific Corp., Westbury, NY). Some formulations included B-Class CpG 
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oligodeoxynucleotide TLR9 agonists (500 µg/vaccine dose), namely CPG7909 (sequence 
5’-TCG TCG TTT TGT CGT TTT GTC GTT-3’) and CpG10104 (sequence 5’-TCG 
TCG TTT CGT CGT TTT GTC GTT-3’) (Coley Pharmaceutical Group, now Pfizer 
Inc.), in the 3-dose and 2-dose studies respectively. These CpG’s differ by a single 
nucleotide and have similar activity in mice and NHP (H. Davis, unpublished). The to 
change to CpG 10104 in the second study occurred because CPG 7909 had been 
dedicated for immune therapy in oncology indications by Pfizer. For the 3-dose study, 
monkeys (5/group; Table 4-1) were intramuscularly vaccinated at 0, 4, and 12 weeks with 
1 mL of vaccine containing 3 proteins (ABL, 100 µg each) plus CpG/alum or 4 proteins 
(ABLA, 20 or 100 µg) plus alum or CpG/alum. In the 2-dose study, monkeys (3/group; 
Table 4-2) were vaccinated at 0 and 4 weeks with 4 proteins (ABLA, 100 µg) plus 
CpG/alum (2 different alum ratios). Both studies included a non-vaccinated control group 
(CpG/alum without proteins) and a positive control group receiving Dryvax® (Lot # 
4020075; CDC) administered at a single time (day 0) by scarification (~2.5x105 pfu live 
VACV) with 15 pricks between the shoulder blades using bifurcated needle. (At the time 
of initiation of these studies, Dryvax was the only FDA approved vaccine for smallpox. 
ACAM2000 has since replaced Dryvax and is considered to have similar 
immunogenicity. All monkeys were bled prior to vaccination, 2 weeks after each 
vaccination, and just prior to challenge for immunogenicity measures. 
 
MPXV challenge 
Anesthetized monkeys were challenged 5 weeks (3-dose study) or 4 weeks (2-dose study) 
after the last subunit vaccine dose by intravenous infusion into the saphenous vein of 
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Table 4-1. Three-dose vaccination study (5 monkeys/group) 
1. Group number and abbreviations of vaccine type used in text 
2. Protein where A, B, L, A stands for A33, B5, L1, A27, respectively. 
3. Adjuvant where CpG/alum stands for CPG 7909 and aluminum hydroxide (Alhydrogel). 
4. PRNT50, pre-challenge (day 121) 50% plaque reduction neutralizing titer against MPXV. 
5. TNTC, too numerous to count. a. Three control animals needed to be euthanized on day 11; b. 1 on day 
13; and c. 1 on day 15. 
6. For calculation of mean and median value, the lesion count was set at 500 for the monkey with TNTC 
lesions on day 12. 
7. One in ABLA/alum only needed to be euthanized on day 13. 
* Lesions present are mostly or only scabs 
 
 
Mean / Median number of 
lesions  
 
Vaccine formulation 
Number of lesions in 
individual monkeys 
 
Group1 
 
Protein2 
Protein 
amount 
(µg/protein) 
 
Adjuvant3 
 
 
Monkey 
number 
 
 
PRNT504 
 
Day 6 
 
Day 9 
 
Day 12 
4342 <10 TNTC5 TNTC5 TNTC5b 
4348 <10 116 TNTC5a  
4354 <10 TNTC5 TNTC5a  
4357 <10 TNTC5 TNTC5 TNTC5c 
 
 
1. Control 
 
 
- 
 
 
- 
 
 
CpG/alum 
4364 <10 TNTC5 TNTC5a  
  7/2 0/0 0/0 
4347 208 2 0 0 
4353 140 0 0 0 
4362 351 0 0 0 
4369 <10 31 0* 0 
 
 
2. Dryvax 
 
 
Dryvax 
 
 
- 
 
 
- 
4371 313 2 2 0 
  11/3 32/17 3/0 
4345 1,895 3 26 0* 
4351 17,501 15 7 4* 
4360 297 1 17 0* 
4363 1,847 0 2 0* 
 
 
3. ABLA 
(100) 
 
 
ABLA 
 
 
100 
 
 
CpG/alum 
4367 132 34 108 10* 
  11/3 25/21 12/0 
4346 6,613 3 49 0* 
4352 1,836 0 0 0 
4361 3,744 3 12 4* 
4368 281 6 21 0* 
 
 
4. ABLA 
(20) 
 
 
ABLA 
 
 
20 
 
 
CpG/alum 
4370 326 45 99 54* 
  35/15 95/73 100/146 
4344 544 4 7 13* 
4350 1,728 0 2 16* 
4356 455 128 312 TNTC7 
4359 279 15 73 14* 
 
 
5. ABLA 
(alum 
only) 
 
 
ABLA 
 
 
100 
 
 
alum only 
4366 123 29 80 8* 
  34/19 167/179 180/224 
4343 287 19 180 224* 
4349 1,054 46 323 12* 
4355 247 10 179 404* 
4358 30 2 2 0 
 
 
6. ABL 
(100) 
 
 
ABL 
 
 
100 
 
 
CpG/alum 
4365 193 95 152 258* 
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Table 4-2. Two-dose vaccination study (3 monkeys/group) 
 
 
1. Group letter and abbreviations of vaccine type used in text 
2. Protein where ABLA stands for A33, B5, L1, A27 
3. Adjuvant where CpG/alum stands for CpG 10104 and aluminum hydroxide (Alhydrogel), used at either 
8.25 µg of aluminum ion/ µg of protein as in the study in Table 4-1 or at 16.5 µg of aluminum ion/ µg of 
protein to increase the amount of aluminum hydroxide. 
4. PRNT50, pre-challenge 50% plaque reduction neutralizing titer against MPXV. 
5. TNTC, too numerous to count. The three control animals needed to be euthanized on day 8. 
* Lesions present are mostly or only scabs 
 
 
 
 
 
 
Vaccine formulation 
 
Number of lesions in 
individual monkeys 
 
Group1 
 
Protein2 
 
Protein 
amount 
(µg/protein) 
 
Adjuvant3 
 
 
 
 
Monkey 
number 
 
 
 
 
PRNT504 
 
Day 6 
 
Day 
10 
 
Day 
14 
4372 <10 
4376 <10 
 
A. Control 
 
- 
 
- 
 
CpG/alum 
4380 <10 
 
TNTC5 
  
4381 383 13 0* 0* 
4382 102 21 0 0 
 
B. Dryvax 
 
Dryvax 
 
- 
 
- 
4383 497 18 0* 0 
4377 9,387 0 5 0* 
4378 151 5 11 0* 
C. ABLA 
(8.25) 
 
ABLA 
 
100 
 
CpG/alum 
(8.25) 
4379 1,440 0 13 0 
4373 1,800 36 0* 0* 
4374 7,235 24 21* 0* 
D. ABLA 
(16.5) 
 
ABLA 
 
100 
 
CpG/alum 
(16.5) 
4375 1,984 0 0 0 
 98 
1.0 mL media containing 2x107 pfu MPXV (NR523, BEI Research Resources 
Repository, Manassas, VA). The challenge inoculum, which was back titered on Vero E6 
cells using a plaque assay to confirm dose, was selected to be lethal and indeed all control 
animals and one monkey receiving ABLA/alum required euthanasia upon meeting a 
predetermined set of criteria of disease progression. Post-challenge, blood was drawn 
every third day and DNA extracted from 200 µl of blood for viral load (VL) 
determination by real-time PCR (149). The detection limit of the viral load assay was 
5000 genome copies/mL blood. Animals were monitored for activity, temperature, 
weight, appetite, and development of pock lesions. 
 
Antibody ELISA 
Standard ELISA determinations used as capture antigens either purified VACV 
(0.6 µg/mL in PBS) or recombinant proteins (A33, B5, or L1 at 2.5 µg/mL; or A27 at 
0.625 µg/mL) in PBS coated overnight at 4 oC. After blocking, 2-fold dilutions of sera 
were incubated for 1 hr at 37 oC. After extensive washes, the secondary antibody, HRP-
conjugated goat anti-monkey IgG (KPL) at 1:2000 was incubated for 1 hr at 37 oC 
followed by color development with ABTS substrate (Sigma) for ~20 min at RT. IgG 
isotypes were determined by coating plates with non-his tagged versions of B5 or L1 at 1 
µg/mL and after incubation with sera, HRP-conjugated anti-human total IgG, IgG1, 
IgG2, IgG3, or IgG4 (Binding Site, Birmingham, UK) diluted at 1:1000 was added and 
incubated for 1 hr at 37 oC. 
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Depletion of sera of anti-L1 antibodies 
Recombinant L1 protein (1 mg) was coupled to 0.5 grams of CNBr-activated 
Sepharose 4B beads (Amersham Biosciences) following the manufacturer’s instructions. 
Mock-coupled beads were processed similarly except without protein addition. Beads 
were washed and resuspended in 500 µL PBS. Equal volumes of sera from the five 
monkeys in each of the ABLA/CpG/alum or ABL/CpG/alum groups in the 3-dose study 
were combined, heat inactivated, and 20 µL of pooled serum was incubated with 180 µL 
of L1-coupled or mock-coupled sepharose beads overnight at 4°C. Beads were pelleted, 
the supernatant collected, and L1 depletion confirmed by L1 or A27 ELISA as above, 
except plates were coated with each protein at 1 µg/mL. Supernatants, stored at 4 °C, 
were used for neutralization experiments. 
 
Virus neutralization 
For MXPV 50% plaque neutralization reduction titers (PNRT50), 4-fold dilutions 
of sera (in 225 µl of media) were mixed with 225 µl purified MPXV MV (450 pfu/well). 
After overnight incubation at 37 oC, 100 µl was removed and plated in triplicate on Vero 
cells for titering. VACV (WR) MV was used in neutralization studies with the L1-
depleted and control depleted sera. MV neutralization assays were carried out in triplicate 
in a final volume of 100 µl containing ~200 pfu of MV, dilutions of sera from individual 
monkeys at 1:20 to 1:2000, and incubated for 2 hr at 37 °C. Samples of 90 µl were titered 
on confluent wells of a 6-well tissue culture plate. After 36 to 48 hrs, wells were stained 
with crystal violet, plaques counted, and normalized to control wells that contained MV 
incubated in media alone. EV neutralization was carried out with VACV EV. EV was 
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isolated from VACV (strain IHDJ) infected RK13 cells in MEM (without FBS) as 
previously described (113). The media from infected cells was clarified by low speed 
centrifugation and EV was titered in the presence of the MV neutralizing monoclonal 
antibody (mAb) 2D5. EV neutralization assays were carried out in triplicate in a final 
volume of 100 µl containing ~200 pfu EV, the indicated dilution of sera from individual 
monkeys, the anti-L1 mAb 2D5 (to neutralize contaminating MV), and with or without 
10 µl of guinea pig complement (Complement Technology, Inc., Tyler, Texas) for 30 min 
at 37 °C. 90 µl of each sample were then titered. 
 
Statistical analysis  
For the 3-dose study (5/group), statistical analyses were performed with SASTM 
Version 9.1 using an alpha =0.05, except where indicated. The dilution ratios for ELISA 
proteins at an optical density (OD) =0.2 were calculated by point-point regression 
between ELISA OD readings immediately <0.2 and >0.2 OD. The dilution values 
calculated at OD =0.2 were used for statistical analyses. A dilution of 0 was given where 
ELISA optical density readings were <0.2. Group median dilutions, PRNT50 levels, and 
viral loads were compared by Kruskal-Wallis ANOVA. Pair-wise comparisons for 
significant differences in viral loads across groups were performed for Groups 1-6 
(Dunn’s test). Significant changes in PRNT50 levels from a baseline level at day 98 were 
tested by Wilcoxon Rank Signed Test. Kaplan-Meier survival plots were calculated for 
vaccination groups following MPXV challenge (days 0-27) and survival curves for each 
vaccination group were compared by Cox-Mantel test; Spearman's rank-order correlation 
test was used on the log[PRNT50] versus lesion numbers and viral loads at day 6 and day 
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9 post-challenge (GraphPad PrismTM, Version 5). The effect of vaccination group on 
weight and temperature were tested with a repeated measures analysis of variance (PROC 
MIXED, SASTM). For MV neutralization assays, statistical differences in plaque number 
were calculated with the Student’s t-test. 
 
Results 
Vaccine safety 
The adjuvanted subunit vaccines were well tolerated by all animals with no 
adverse reactions. 
 
Challenge with MPXV 
Negative and positive vaccine controls.  
We analyzed clinical symptoms and survival post-challenge (Fig. 4-1A), lesion 
counts (Fig. 4-1B), and viral loads (Fig. 4-2) in both vaccinated and non-vaccinated 
animals. The non-vaccinated control animals (Group 1) exhibited typical signs of MPXV 
disease and experienced depression, lethargy, and pock lesions after challenge that 
became too numerous to count (TNTC) by day 6 (Table 4-1, Fig. 4-1B). Peak viral loads 
(VL) were between 107 and 109 genome copies/mL by day 9 or 12 (Fig. 4-2). These 
animals met endpoint criteria for euthanasia between days 11 and 15 (Fig. 4-1A). 
Animals vaccinated with the positive control gold standard Dryvax vaccine (Group 2), all 
survived and exhibited little or no clinical signs of infection; the few pock lesions that 
developed healed quickly (Fig. 4-1B), and had no measurable VL at any time except for 
animal #4353 with a VL of ~2x104 genome copies/mL on day 3 post-challenge (p.c.) 
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(Fig. 4-2). When we compared Group 2 with Group 1, there were statistically lower viral 
loads in Group 2 at all time points (Dunn’s multiple comparison test; P<0.05). Similar 
results were seen for negative and positive control groups in the smaller 2-dose study 
where all non-vaccinated control monkeys (Group A) met endpoints that required 
euthanasia on day 8 p.c. and the Dryvax-vaccine protected all the monkeys (Group B) 
from MPXV disease (Table 4-2). 
 
Subunit vaccine provides protection.  
All animals vaccinated with three doses of subunit vaccines containing CpG/alum 
(Groups 2, 4, & 6) survived (χ2(1,10) =10.03; P=0.0015 relative to control Group 1), and 
all but one in Group 5 (ABLA/alum) survived (χ2(1,10) =6.872; P=0.0088) (Fig. 4-1A). 
Groups vaccinated with ABLA/CpG/alum also had statistically lower VL than controls at 
days 3, 5, and 12 p.c. (Dunn’s multiple comparison test; P<0.05; Fig. 4-2, Groups 3 & 4). 
In all groups, monkeys with the highest VL exhibited the most lesions. 
 
Benefit of CpG.  
In the 3-dose study, addition of CpG to the tetravalent vaccine resulted in more 
consistent control of infection than with alum as the sole adjuvant as indicated by fewer 
lesions (Table 4-1, Fig. 4-1B) and lower VL (Fig. 4-2; Groups 3 & 4 versus 5). Indeed, 
with just alum, the VL at all time points p.c. were not significantly different than non-
vaccinated controls (Dunn’s multiple comparison test; P>0.05). Also, a dose of 20 
µg/protein with CpG and alum gave equivalent results for survival, lesions, and VL as a 
dose of 100 µg/protein (Groups 3 versus 4) indicating that lower antigen doses can be 
 103 
 
Figure 4-1. Kaplan-Meier survival analyses and pock lesion summary.  
A. Kaplan-Meier survival plots following MPXV challenge for the 3-dose study with 5 
monkeys/group. Solid line with squares: Dryvax (Group 2), ABLA/CpG/alum (Groups 3 
& 4), and ABL/CpG/alum (Group 6); Dashed line with triangles: ABLA/alum (Group 5); 
Dotted line with circles: CpG/alum control (Group 1). B. Frequency of each lesion 
category for vaccination groups at days 0-27 post-challenge. The upper and lower 
quartiles of lesion frequencies for numeric lesion data were calculated and plotted. The 
25th (1 to ≤ 7 lesions) and 75th percentiles (≥ 241 lesions) were used to recode the 
numeric lesion data into low (≤ 25th), medium (25th -75th) and high (≥75th) lesion 
categories. For this analysis, lesion counts that were recorded as “TNTC” (too numerous 
to count) were set at ≥500 lesions. High lesions (≥241) were observed for all animals in 
Group 1 by day 9 post-challenge. High lesions were observed in 1 of 5 animals in Group 
5 by day 9 and 2 of 5 animals in Group 6 by day 12. All animals in Group 3 experienced 
low (≤7) to medium (<241) lesions by day 9. All lesions of surviving animals in Groups 
2-6 were healed by day 24, post-challenge. C. Kaplan-Meier survival plots following 
MPXV challenge for the 2-dose study with 3 monkeys/group. Solid line with squares: 
Dryvax (Group B) ABLA/CpG/alum (Groups C & D); Dotted line with circles: 
CpG/alum control (Group A). 
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Figure 4-2. Viral load on days 0-27 post-challenge.  
Graphed are the post-challenge viral load by group and monkey. The detection limit of 
the viral load assay was 5000 genome copies/mL blood. Median VL and inter-quartile 
ranges were determined and Dunn’s multiple comparison test was performed on 
vaccination pairs where a significant main effect of vaccination groups was found. A 
higher viral load was found for Group 1 compared to (i) Group 2 (Dryvax) at days 3-15 
(P<0.05); (ii) Group 3 (ABLA(100)/CpG/alum) at days 3, 6, and 15 (P<0.05); and (iii) 
Group 4 (ABLA(20)/CpG/alum) at day 3 and 15 (P<0.05). * P<0.05, ^ P<0.01, + 
P<0.001 
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used when CpG is included. In the 2-dose study we compared CpG containing vaccines 
with two doses of alum, either 8.25 aluminum ion/µg of protein (as used in the 3-dose 
study) or 16.5 (Table 4-2, Groups C and D). We found no difference in protection (Fig. 4-
1C, Table 4-2), although only 3 monkeys per group may be inadequate to detect 
differences. 
 
Trivalent versus tetravalent protein vaccines and three versus two-dose regimen.  
The CpG/alum adjuvanted trivalent vaccine protected animals from death, as did 
the tetravalent vaccines (Fig. 4-1B, Groups 3, 4, and 6), but there were fewer lesions and 
lower VL with ABLA (20 or 100 µg) than with ABL (100 µg), suggesting a role for A27 
in protection. In the 2-dose study, the tetravalent vaccine (100 µg/protein) with 
CpG/alum provided excellent protection. One monkey showed no lesions at any time 
tested (Fig. 4-1C, Table 4-2). While this study was run separately from the 3-dose study, 
the results were similar for both. 
 
Vaccine immunogenicity and correlation with protection. 
Since protection from secondary poxvirus infections is primarily antibody-
mediated (103,107,149), we focused on evaluating antibody responses. In the 3-dose 
study, animals vaccinated with a single Dryvax scarification developed VACV-specific 
antibodies early (day 14) but as expected, titers did not increase at later times (data not 
shown). Monkeys vaccinated with subunit vaccines had no detectable VACV-specific 
antibody responses post-prime but exhibited strong responses by day 42 (2 weeks post 1st 
boost). These titers increased further by day 98 (2 weeks post 2nd boost). While there 
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were no significant differences between groups in antibody titers to individual proteins, 
due to high variability and small number of animals, we did note trends indicating that 
100 µg/protein of the tetravalent vaccine was better than 20 µg/protein, and CpG/alum 
was better than alum alone, with the highest titers being found with 
ABLA(100)/CpG/alum (data not shown). 
 
Neutralization activity correlates with protection.  
The tetravalent vaccines adjuvanted with CpG/alum (Groups 3 & 4) were the only 
formulations that yielded better pre-challenge neutralization titers against MPXV MV 
than non-vaccinated controls (P<0.01) (data not shown). The 100 µg antigen dose 
developed the best pre-challenge responses, which did not increase appreciably post-
challenge. In contrast, while pre-challenge PRNT50 values for Dryvax were not 
“statistically significant” (but at similar levels to published studies (222,297)), the post-
challenge (day 9, 18 and 27 p.c.) PRNT50 values with Dryvax increased over pre-
challenge values (P<0.05) and were significantly higher than non-vaccinated controls 
(P<0.001). They were also higher than the titers of the ABL/CpG/alum group (P<0.05). 
There was an inverse relationship between prechallenge PRNT50 and post-challenge VL 
or lesion numbers (Fig. 4-3). 
 
Antibody isotype contributes to protection.  
CpG, a Th1 adjuvant, had a clear effect on protection (Table 4-1, Groups 3 & 4 
vs. 5). Although antibody isotype is a less clear indicator of Th-bias in primates than 
mice, we examined anti-B5 and anti-L1 specific responses after the third vaccine dose 
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(day 98). We found IgG1 and IgG2, but not IgG3 and IgG4, which possibly were not 
detected due to use of human reagents. The anti-B5 isotype response was more 
homogeneous in vaccines formulated with CpG/alum than with alum alone. Moreover, 
the CpG/alum adjuvanted vaccine showed a consistent IgG1:IgG2 ratio >2 (Fig. 4-4A), 
whereas the ratio of IgG1:IgG2 for alum alone was closer to one (Fig. 4-4B). 
Importantly, IgG1 responses alone were consistently high in all NHPs vaccinated with 
CpG/alum adjuvanted vaccine, while only 2 of 5 NHPs vaccinated with alum only 
showed high IgG1 titers. Antibody isotype determines function, and IgG1 antibodies are 
known to activate complement (189). When we used concentrations of sera that did not 
efficiently neutralize EV, addition of active complement consistently enhanced EV 
neutralization in animals vaccinated with ABLA(100)/CpG/alum but had an enhancing 
effect in only 2 of 5 animals that received ABLA(100)/alum (Fig. 4-4C). 
 
Anti-A27 antibodies do not neutralize virus.  
While the trivalent and tetravalent vaccines adjuvanted with CpG/alum protected NHP 
from death after lethal challenge with MPXV, we were surprised that pock lesion counts 
with the trivalent vaccine (Group 6) were much higher than with the tetravalent vaccine 
(Group 3, Table 4-1). In mice, A27 could not substitute for L1 in a trivalent vaccine, 
possibly because the anti-A27 antibodies do not neutralize MV (110). To determine 
whether the monkeys developed a neutralizing antibody response to A27, we depleted 
anti-L1 antibodies by passing pooled sera from the vaccinated groups through L1-
coupled (or uncoupled) sepharose beads. ELISA showed no remaining anti-L1 titers, but 
titers to A27 were unchanged (data not shown). We found that if L1 antibodies were  
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Figure 4-3. Relationship between PRNT50, lesion number, and viral load.  
Post-challenge lesion counts (open circles) and viral loads (solid triangles) at day 6 (A) 
and day 9 (B) are plotted against the log of the pre-challenge PRNT50. Various colored 
symbols represent each different vaccination group: Group 1 (adjuvant only) black; group 
2 (Dryvax) blue; group 3 (ABLA(100)/CpG/alum) red; group 4 (ABLA(20)/CpG/alum) 
purple; group 5 (ABLA/alum) green; group 6 (ABL/CpG/alum) orange. For this analysis, 
“TNTC” lesions were set at 500 lesions. Correlations between prechallenge neutralization 
(log[PRNT50]) and day 6 lesions (r = -0.5433 P=0.0019) and viral loads (r = -0.3997 
P=0.0287) and day 9 lesions (r = -0.3929 P=0.0318) and viral loads (r = -0.3928 
P=0.0318) were statistically significant. 
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Figure 4-4. Protein vaccines adjuvanted with CpG/alum provide higher IgG1 to 
IgG2 ratios that result in more consistent complement-enhanced neutralization 
of EV.  
A. IgG1 and IgG2 isotype responses to B5 in Group 3 (ABLA(100)/CpG/alum) at day 98 
(2 weeks after the second boost). B. IgG1 and IgG2 isotype responses to B5 in Group 5 
(ABLA/alum) at day 98 (2 weeks after the second boost). Solid lines with solid symbols: 
IgG1 responses. Dashed lines with open symbols: IgG2 responses. C. EV neutralization 
by NHP sera on day 98 (2 weeks after the second boost) in the absence and presence of 
complement (C’). Error bars represent standard deviation. 
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depleted, sera no longer was able to neutralize MV (Fig. 4-5), indicating that the 
monkeys did not develop a neutralizing antibody response to A27. 
 
Discussion 
Recent life-threatening complications (298,299) with the FDA approved live VACV 
vaccine highlight the need for safer vaccines against orthopoxviruses, for which the threat 
of infection exists through zoonosis (e.g., monkeypox) or inadvertent or purposeful 
release of smallpox. The highly attenuated MVA, which does not produce infectious 
virions in human cells, is thought to be a safer attenuated VACV vaccine (268). 
However, it continues to rely on a live virus and requires 1000-times the dose of the 
current live VACV vaccine. Subunit vaccines comprising recombinant protein antigens 
may be safe for all individuals and could be a useful future alternative, particularly if live 
virus vaccines are no longer acceptable at those times. Such a subunit vaccine would be 
useful in the pre-event setting to provide baseline immunity should newly introduced 
orthopoxviruses cause serious human infections. Also, a protein vaccine might enhance 
the safety of a live vaccinia vaccine in the event that a fully replication competent 
vaccine be deemed necessary to control a significant smallpox outbreak. Alternatively, it 
could also be useful to boost responses in the older population who had received 
childhood smallpox vaccines, leaving potentially limited supplies of live vaccine for 
those at greatest risk. Herein, we have shown the ability of a trivalent (A33, B5, and L1 
(ABL)) or tetravalent (ABL+A27 (ABLA)) protein-based adjuvanted vaccine to elicit 
humoral immune responses in monkeys that protect against lethal MPXV challenge. 
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Figure 4-5. Antibody against A27 does not neutralize MV.  
MV neutralization by NHP sera on day 98 from group 3 (ABLA(100) CpG/alum). Sera 
were passed through L1-coupled sepharose beads or control beads. It was then used at 
dilutions of 1:10, 1:100, and 1:1000. Only control treated sera was still capable of 
neutralizing MV at 1:10 and 1:100 dilutions when compared to input virus treated with 
media alone. * p<0.05.  
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While a direct correlate of immunity to poxvirus infections is still unknown, our 
data suggest that the best results are obtained when the protein vaccine elicits a high 
amount of IgG1 isotype antibodies that are able to neutralize EV in the presence of 
complement. These results are consistent with findings by the Crotty group showing the 
importance of the Fc domain in antibody protection of poxvirus infections (124,125). 
They found that anti-B5 mAbs (that poorly neutralized EV on their own) were quite 
potent at neutralizing EV in the presence of complement. Furthermore, treatment of mice 
with anti-B5 mAbs with complement fixing isotypes were better at protecting mice from 
VACV challenge. In future studies of smallpox vaccines in humans or NHPs, inducing a 
high titer of IgG1 antibodies may correlate with improved protection for the vaccine and 
thus IgG1 titers should be evaluated. 
Our earlier work in mice indicated that ABL and ABLA (both formulated with 
CpG/alum) provided similar protection from intranasal challenge with VACV or 
ectromelia virus (110). Thus we were surprised that the tetravalent vaccine clearly 
outperformed the trivalent protein vaccine for clinical outcomes (pock lesions and VL) in 
NHPs. The role of A27 is not clear since we found that anti-A27 antibodies did not 
neutralize MV. It is noteworthy that a recent report from the Moss group found 
neutralizing antibodies to A27, but the protein was still less protective than the L1 protein 
(137). T-helper epitopes within A27 may improve responses to other antigens that 
enhance protection. Another possibility is that the addition of A27 resulted in 
physiochemical changes in the tetravalent vaccine formulation that enhanced protection. 
Studies to better understand this are underway. Our results are consistent with others 
using the same antigens. ABL/CpG/alum provided similar protection to that reported by 
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the Moss group with ABL/QS21 (a saponin adjuvant) (105), although it is important to 
note several differences in study design. These include adjuvant formulation, vaccination 
schedules (dose number and time between doses), the number of NHP, and relative 
lethality of challenge dose. Likewise, our ABLA results are similar to those obtained in a 
smaller study by the Franchini group using MPXV orthologs of the same four VACV 
proteins used here (149). 
Aluminum hydroxide, a well-established adjuvant, provides reasonably good 
protection, but adding CpG provides additional benefit and improved protection. 
CPG7909 is a B-Class CpG oligodeoxynucleotide that has proven in clinical studies to 
significantly enhance (~5 to 10-fold) humoral responses against several different antigens 
(300,301). CpG10104, a related molecule with similar pharmacological effects, is 
currently under development as an adjuvant for infectious disease vaccines. While not 
compared side-by-side in the same study, our results support their similar activities. The 
Franchini study involved DNA prime/protein boost and a slightly higher MPXV 
challenge dose, but two groups were vaccinated with protein adjuvanted with either 
aluminum hydroxide (n=3) or CpG (2 mg/animal of CPG7909, also known as CpG2006; 
n=4). More than 25 lesions were seen in 3 of 3 (protein/alum) and 3 of 4 (protein/CpG) 
challenged monkeys in the Franchini study and 3 of 5 (protein/alum) monkeys in our 
study, but only 4 of 16 (protein/CpG/alum) challenged monkeys in our studies. Thus, 
there appears to be a benefit for including both alum and CpG in subunit vaccine 
formulations. 
Intravenous challenge has been widely used to study smallpox therapies and 
vaccines because it more closely mimics some aspects of smallpox disease (104-
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107,149,240,241,294,302-305). However, there are disadvantages. The challenge dose is 
high and essentially starts the disease process at a stage closer to the secondary viremic 
phase of smallpox, therefore setting a very high bar for a preventative vaccine. 
Conversely, the outcome of intravenous challenge may depend more heavily on antibody 
responses against MV. Other NHP challenge models, like respiratory challenge, are being 
developed (233,239,306,307) and should be useful to further test effectiveness of subunit 
orthopoxvirus vaccines. For FDA approval of future generation smallpox vaccines by the 
“animal rule”, multiple animal models with various modes of challenge will likely be 
needed. 
In conclusion, we found that as few as 2 doses of an adjuvanted protein-based 
subunit vaccine protected NHP from a lethal MPXV challenge. Such a vaccine would be 
valuable in a setting where it is difficult to screen large populations to identify those with 
increased risk of complications from live VACV vaccination. It could also be used to 
safely provide base-line poxvirus immunity and for immunization of individuals refusing 
VACV. 
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Chapter Five: Concluding Remarks  
 
A summary of results contained within, future directions, and implications for future 
vaccine design and licensure 
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Introduction 
 Antibody plays a critical role in protection from secondary poxvirus infection. 
This thesis focused on antibody against two different EV protein targets: A33 and B5. 
The EV form of the virus, responsible for dissemination within a host, is relatively 
resistant to direct neutralization by antibody. Therefore, antibodies against proteins found 
on EV utilize Fc-dependent mechanisms to enhance their protective effects. These Fc-
dependent mechanisms include the activation of complement to neutralize EV particles 
and lyse infected cells and the interaction with FcRs to direct an innate cellular response 
against EV particles or infected cells. In chapter two, I reviewed future generation 
smallpox vaccines. Many of the future generation subunit vaccines rely on antibody 
responses to confer protection. In chapter three, we showed that production of IgG2a 
isotype antibody (Th1-biased immune response) by protein vaccination of mice 
correlated with protection from lethal challenge with VACV. We then showed that IgG2a 
containing polyclonal antibody against A33 or B5 could neutralize a large input of virus 
only in the presence of active complement. Additionally, we showed that neutralization 
by complement occurred by virolysis for antibody against A33 and could occur by 
opsonization (coating) with antibody against B5. We attributed this difference to the 
different amount of protein expressed on the surface of EV and showed that manipulation 
of the amount of B5 antibody bound to EV could change the activation steps by which 
complement neutralizes EV (Fig. 5-1). We went on to show in chapter three that both 
complement and FcRs play a role in the ability of antibody to protect mice from VACV 
challenge. In chapter four, we showed that vaccination with a protein-based smallpox  
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Figure 5-1. Model of complement-dependent EV neutralization by anti-B5 or 
anti-A33 antibody.  
Antibody against the surface proteins B5 and A33 can neutralize EV more effectively 
after activation of complement. We hypothesized that the amount of antibody bound to 
the EV surface accounts for differences in the required complement activation steps. (A) 
Anti-B5 antibody binds the B5 surface proteins on EV, but does not efficiently block 
infection, due to an insufficient number of B5 proteins available for antibody to bind and 
completely coat the particle. Activation of complement by binding of C1q to the Fc 
portion of the antibody and subsequent efficient deposition of C3 on the surface of the 
EV virion can block infection and neutralize virus. (B) A33 protein is found at lower 
levels than B5 protein on EV virions. Anti-A33 antibody binds the A33 surface proteins 
on EV, but does not block infection, again due to an insufficient number of A33 proteins 
available for antibody to bind. Activation of complement by antibody binding C1q and 
deposition of C3 alone is also insufficient to block infection. We hypothesize that this is 
due to the smaller numbers of antibody bound to EV and, therefore, the inability to 
efficiently activate complement and deposit enough C3 on the EV virion surface. Instead, 
the complement activation needs to proceed to the insertion of the MAC and lysis of the 
outer membrane of EV. Anti-MV neutralizing antibody such as anti-L1, if present, is then 
capable of interacting with the revealed MV virion and neutralization can occur. (C) At 
lower concentrations of anti-B5 antibody, a smaller number of the B5 proteins on the EV 
surface are bound by anti-B5 antibody. This scenario recapitulates the smaller numbers of 
anti-A33 antibody bound to EV as found in panel B. As with anti-A33 antibody, C1q 
binding and C3 deposition is inefficiently activated and cannot occupy the entire EV 
surface. For neutralization to occur, complement activation needs to proceed to insertion 
of the MAC and lysis of the outer EV membrane. MV neutralizing antibody such as anti-
L1, if present, can then neutralize the released MV virion. 
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vaccine protected NHP from MPXV challenge and viral loads/lesion counts were 
inversely correlated with MV neutralizing antibody titers (Fig 4-3). The inclusion of CpG 
in the protein vaccine formulation induced a more homogeneous Th1 antibody response 
against B5, characterized by an IgG1:IgG2 ratio >2 and these sera were capable of 
neutralizing EV in the presence of complement. This may have partially accounted for 
the better protection from morbidity and mortality for those NHP receiving CpG as part 
of their vaccine formulation. Lastly, we found that protein vaccination formulations that 
included A27 enhanced protection in NHPs, but this protection was not due to the 
development of a neutralizing antibody response against A27. In this section, I will 
review the major conclusions from chapters three and four and discuss their implications. 
Additionally, I will discuss potential future directions.  
 
Complement-dependent EV neutralization 
 EV is relatively resistant to direct neutralization by antibody. At high 
concentrations, some monoclonal and polyclonal antibody raised to B5 can directly 
neutralize EV when assays use small numbers of EV (44,109,113,166). Interestingly, 
while A33 has been shown to be an important target of protective antibody responses, 
anti-A33 antibody has not been shown to directly neutralize EV. One proposed 
mechanism of the protective effect of anti-A33 antibody is the antibody preventing the 
release of EV from the infected cell (34). Another mechanism might be by complement-
enhanced neutralization. Polyclonal rabbit antibody against A33 in the presence of 
complement was found to lyse the outer membrane of EV, exposing the MV virus within. 
If MV neutralizing antibody was present, these virions were neutralized (97). 
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Complement can also enhance EV neutralization by anti-B5 antibody. Recent work by 
Benhnia, et. al. described an anti-B5 monoclonal antibody that could not directly 
neutralize EV, but could neutralize in the presence of C’. However, they found that EV 
neutralization did not require lysis of the EV outer membrane (125). Because C’-
dependent neutralization of EV by anti-A33 antibody appeared to require virion lysis and 
anti-B5 antibody and complement could neutralize by opsonization and were studied 
using small numbers of EV particles in the presence of a large amount of antibody 
generated by different methods, we examined the ability of anti-A33 and anti-B5 
polyclonal antibody generated after active vaccination of mice to neutralize large 
numbers of EV in the presence of complement. We found that polyclonal sera were able 
to neutralize EV in presence of active complement resulting in approximately a log 
reduction in infectivity (Fig. 3-5). Because these experiments were performed in the 
presence of a neutralizing MV antibody, we used complement depleted of C5 to 
determine that indeed anti-A33 antibody required virolysis for neutralization but anti-B5 
antibody did not. This finding helps explain our observation that vaccinating with B5 
protein was more protective than vaccinating with A33 protein alone (Table 3-1). This 
finding also suggests that the use of anti-A33 antibody therapeutically or in a vaccine 
formulation would benefit from the inclusion of a neutralizing MV antibody or protein 
target to neutralize released MV after C’-mediated lysis of the EV outer envelope. To 
date, the other proteins found on EV have not been found to generate neutralizing 
antibody or to protect mice if given as a vaccine (109,169). It would be interesting to 
determine if antibody to these targets could neutralize EV in the presence of complement 
and explore why they have not been shown to be protective in vivo. 
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 The ability of anti-B5 antibody to neutralize in the absence of C5 suggested to us 
that something about the B5 protein allowed for complement to opsonize (coat) the 
particle and block the ability of EV to infect cells. We hypothesized that because B5 
protein was found at higher amounts on the surface of EV than A33 protein, antibody 
could more completely cover the surface of EV and therefore result in more efficient 
deposition of complement on the EV surface and subsequent neutralization by 
opsonization. Conversely, the lower amount of A33 protein on the EV surface results in 
less antibody on the EV surface and the inability to induce complement deposition on the 
entire surface. EV neutralization would then require the formation of MAC pores and the 
lysis of the outer envelope of EV resulting in the release of MV that is then neutralized 
by MV-neutralizing antibody (Fig. 5-1). In support of this model, we found that by 
reducing the amount of anti-B5 antibody bound to EV, we could force the need of the 
MAC lytic pathway of complement-dependent neutralization. This finding suggests that 
the amount of antibody available to activate complement is important to drive the 
efficient deposition of complement and neutralization of the virion. To further confirm 
our hypothesis, one could overexpress A33 in an attempt to provide more antibody 
targets on the surface of EV. We would expect that anti-A33 antibody along with 
complement could then neutralize EV by opsonization (coating). Additionally, it would 
be interesting to determine the importance of formation of the MAC in vivo for protection 
from challenge by anti-A33 and anti-B5 antibody. To examine this, mice genetically 
deficient in the C5 complement component could be used, albeit other functions of C5 
would need to be considered. This would also be a way to begin to examine the 
importance of direct complement-dependent virus neutralization vs. the ability of 
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complement to lyse infected cells. The presence of host regulators of complement found 
on EV particles (46) and a viral complement regulator on infected cell surfaces (193) 
suggests that both mechanisms are important for protection from infection. Overall, our 
findings demonstrate how the relative expression levels of different viral surface proteins 
can alter an important host-pathogen interaction.  
 
Fc-dependent protection by antibody in mice 
 Active or passive immunization against the EV proteins A33 or B5 can provide 
protection from challenge in mice (96,98,105,106,108-110,124,125,138,149,153,159-
162,166-169). Because antibody is inefficient at directly neutralizing EV, Fc-dependent 
effector mechanisms must play a role in protection. Benhnia, et al. found that a 
complement fixing anti-B5 monoclonal antibody could protect mice and that protection 
was partially dependent on complement (125). We hypothesized that protection of mice 
by polyclonal antibody against B5 would also be partially dependent on complement and 
that interaction of antibody with FcRs would account for protection seen in the absence 
of complement. Indeed, mice deficient in the central complement component C3 were 
still partially protected from challenge after active B5 protein vaccination or passive 
vaccination with polyclonal B5 antibody, though not as protected as wild-type mice 
(Figs. 3-9 and 3-10). If polyclonal B5 antibody was passively transferred to FcR 
knockout mice, mice were protected from challenge. However, if complement was 
depleted, protection was completely lost (Fig. 3-11). We additionally examined the 
monoclonal anti-B5 antibody (B126) that Benhnia, et. al. used and found that FcRs were 
important for the in vivo protective effects of this antibody (Fig. 3-12). Together, these 
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results suggest that both complement and FcRs are important for mediating protection by 
antibody against the EV protein B5.  
  While we found a role for FcRs, we did not determine the type of FcR expressing 
cells important for mediating protection. Because we found that IgG2a was important for 
protection in mice, and not IgG1 (Fig. 3-3 and Table 3-1), it’s likely that FcγRIV 
expressing cells are important for protection. These include macrophages, neutrophils, 
monocytes, and dendritic cells. Macrophages have previously been shown to be 
important for protection from primary challenge (211), so it would be interesting to 
determine if they are also important when an antibody response is present. NK cells may 
also help mediate protection through the expression of the low affinity FcγRIII and 
interaction with IgG1 or IgG2a/b. Additionally, these innate cells are known to secrete 
proinflammatory cytokines in response to FcR stimulation, but the cytokines produced 
after infection in the presence of a protective antibody response are currently unknown. 
The cell types involved in FcR-mediated protection could be examined in vitro and in 
vivo. In vitro studies could include the examination of the ability of peripheral 
lymphocyte and myeloid cells taken from wild-type and FcRKO mice to kill infected 
cells in the presence of anti-B5 antibody and/or measure their ability to secrete cytokines 
in response to FcR engagement by flow cytometry and ELISA. In vivo studies could 
determine the ability of anti-B5 antibody to protect after the depletion of innate cell 
subsets, such as macrophages or NK cells.  
 Anti-A33 antibody has been found to neutralize EV in the presence of 
complement (and anti-MV neutralizing antibody) (97) and could induce complement-
dependent lysis of infected cells (160). However, we did not examine the relative 
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importance of complement or FcRs in the ability of anti-A33 antibody to protect mice 
from lethal challenge. While we found that anti-A33 antibody was not as protective as B5 
antibody, others have shown that anti-A33 antibody can be protective at lower challenge 
doses (98,101,109) and can enhance the protection afforded by anti-MV antibodies 
against L1 (98,105,160). It would be interesting to determine if complement and FcRs are 
important in mediating that enhanced protection, as anti-A33 antibody has been shown to 
be able to inhibit the release of CEV virions from the infected cell surface in comet 
inhibition assays. By better understanding the antibody functional requirements necessary 
for protection, we can better design and test new therapeutics and vaccines.  
 
Antibody isotype and function in NHPs 
 Generation of a Th1 immune response is important for recovery from viral 
infections. Therefore, it may be beneficial for viral vaccines to not only elicit antibody, 
but also elicit antibody isotypes driven by a Th1-biased response. In mice this is 
IgG2a/b/c, and in NHP or humans this is IgG1. However, knowing the isotype does not 
always indicate the specific functionality of the response. As we found in chapter three, 
an IgG2b monoclonal antibody did not activate complement like the isotype would 
suggest. Therefore, it’s important to measure both the isotype and the function of the 
antibody response, especially when analyzing the immune response to a vaccine in 
individually genetically diverse NHPs or humans. In Chapter 4, we found that including 
the Th1 stimulating adjuvant CpG in our protein-based vaccine induced an immune 
response that was more Th1-like. While some NHPs that were vaccinated with 
formulations that did not include CpG developed this type of immune response, others 
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did not. By including CpG, we found that vaccination of NHPs generated a homogeneous 
immune response characterized by higher IgG1 than IgG2. We then found that NHPs that 
generated a higher IgG1 response had sera that could fix complement to neutralize EV, 
including all of the NHPs that had CpG as part of their vaccine formulation. In future 
analysis of new smallpox vaccines in NHPs or humans, IgG1 responses should be 
analyzed and functional activity measured. This is especially important for smallpox 
vaccines, as it’s impossible to test the effectiveness of a new vaccine against variola virus 
in humans. In order to receive FDA approval, we must have rigorous animal models to 
test the vaccine efficacy as well as suitable analysis of the immune response to the 
vaccine in order to have the best and most accurate assessment of how the vaccine might 
protect humans from a smallpox infection. 
 Additionally, we found that including A27 protein in the protein vaccine added 
protection from MPXV challenge, but this was not due to production of neutralizing 
antibody. Whether the A27 protein contributed to the stabilization of the vaccine 
formulation, induced a CD4+ or CD8+ immune response, or enhanced MV neutralization 
in a complement dependent fashion is unknown. In the future, it would be beneficial to 
better understand the contributions of each protein in the vaccine for protection of NHPs. 
This would allow for the optimization of the vaccine and allow for better assessment of 
protective immune responses at the clinical testing stages. 
 
In conclusion, this thesis has provided evidence that antibody isotype and 
functional activity are critical for efficient neutralization of EV and contribute to 
protection from lethal poxvirus challenge in mice and NHP. We have also provided a 
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benchmark to further analyze future smallpox vaccine candidates in mice, NHPs, and 
ultimately humans. 
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Appendix: Preliminary results on the production and characterization of a 
recombinant VACV with β-lactamase fused to the core protein A4 
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Introduction 
 Poxviruses enter cells by fusion at the plasma membrane or macropinocytosis 
followed by low-pH induced fusion within macropinosomes (29,51-56). These entry 
mechanisms lead to the poxvirus core penetrating into the cytoplasm of the infected cell. 
Efforts to study the entry of poxviruses would be enhanced with an easy to use, high-
throughput assay that strictly measure the ability of the virus core to enter the cytoplasm.  
 The most commonly used assay relies on measuring reporter gene expression 
(e.g., luciferase or β-galactosidase under the control of an early VACV promoter) (308). 
Therefore, it is a surrogate measure for VACV entry as entry, uncoating, early gene 
expression, and protein translation must all occur. While these reporter assays are easy to 
use, and allow for high-throughput testing, it does not strictly measure entry because of 
the multiple additional steps after entry that are needed for successful reporter gene 
expression. 
  Another assay used to measure entry of VACV is called the “core penetration 
assay” (309). This assay has been used to quantitatively assess the ability of VACV to 
bind and enter cells and does not rely on expression of any genes. Instead, an antibody 
that only recognizes VACV cores that have entered the cytoplasm is used to probe 
recently infected cells. A second antibody against a viral envelope protein is used to 
detect virions that did not enter the cell. Confocal immunofluorescence microscopy is 
then used to manually count the number of viral cores that have entered the cytoplasm 
compared to viral particles that remained outside the cell. While this assay accurately 
assesses entry, it has some limitations. If more than ten to twenty cores enter a single cell, 
it is impossible to accurately count the fluorescent particles. Thus, the number of viral 
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particles that one can infect each cell with is limited. Additionally, the core penetration 
assay is technically difficult, time consuming, and uses potentially limited, precious 
reagents. These factors make it unsuitable for use in a high-throughput format. 
 As an initial step to develop a high-throughput assay that strictly measures the 
penetration of VACV cores into the cytoplasm, we designed and produced a recombinant 
VACV that has β-lactamase fused to the core protein A4. This assay is similar to one 
initially used in HIV entry research, where β-lactamase is fused to the Vpr protein (310). 
Subsequently, this assay has been adapted to study the entry of other viruses through the 
use of psuedotyped HIV virions (311,312) as well as the creation of other viral β-
lactamase fusion proteins (313,314). We chose to fuse β-lactamase to the N-terminal 
domain of the VACV A4 core protein because a recombinant VACV with GFP fused to 
the N-terminal domain of A4 had previously been made and was viable (29). A4 has been 
shown to be one of the most abundant proteins found in mature virus (MV) (315,316) and 
would likely incorporate enough β-lactamase enzyme per virion to be detectable in cells. 
Additionally, substrates that measure β-lactamase activity in live cells are available and 
can quantitatively measure the ability of the core to penetrate into the cytoplasm of live 
infected cells. The following appendix chapter describes the construction and isolation of 
this virus and its initial characterization.  
 
Methods, Results, and Discussion 
Plasmid Construction. 
 To create a recombinant virus expressing β-lactamase fused to the N-terminus of 
A4, a plasmid was constructed using splicing by overlap extension (SOEing) PCR. The 
 130 
resulting plasmid contains the left flanking non-coding sequence of the A4L gene, 
followed by the β-lactamase gene (without a stop codon) fused in frame with the A4L 
coding sequence (with the start codon removed), and finally flanking sequence to the 
right of A4. Additionally, we included an E. coli gpt (guanine phosphoriboxyltransferase) 
selection cassette outside of where homologous recombination was to take place to 
increase the ability to isolate a recombinant VACV with β-lactamase fused in frame to 
the A4L gene (Fig. 6-1). To construct this plasmid, SOEing PCR was used to generate 
three separate PCR fragments from VACV WR strain genomic DNA or pUC19 DNA (β-
lactamase gene) using the primers in Table 6-1. The three PCR products generated were: 
(1) A 465 base-pair PCR product containing the left-flank non-coding A4L sequence and 
the first part of the β-lactamase gene was amplified using olMC192 and olMC193 from 
VACV WR strain genomic DNA. (2) A 789 base-pair PCR product containing the β-
lactamase gene (without stop codon) was amplified using olMC194 and olMC195. (3) A 
1230 base-pair PCR product containing the last part of the β-lactamase gene (without a 
stop codon), a linker that would encode three glycines, the A4L coding sequence (without 
a start codon), and the right flank non-coding sequence of A4L was amplified using 
olMC196 and olMC197. These three PCR products were then mixed in a single PCR 
reaction and the full length ~2.4-kb fragment was amplified using olMC192 and 
olMC197. The final product was cloned blunt-end into pCR-BLUNT II-TOPO 
(Invitrogen), confirmed by sequencing the full 2.4-kb insert, and named pMC243. 
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Figure 6-1. Diagram of pMC245.  
Shown is the 2.4-kb insert for recombination of the β-lactamase-A4 gene into wild-type 
VACV. The A4 left flank includes the natural A4 promoter sequence before the β-
lactamase gene. The β-lactamase gene has a start codon, but no stop codon so that there is 
read-through to the A4 coding sequence. The A4 coding sequence open reading frame 
does not have a start codon, but does have the natural A4 stop codon. The flanking 
sequence to the right of A4, along with the left flanking sequence drives homologous 
recombination into the virus. A gpt selection cassette driven by the VACV P7.5 promoter 
was ligated into the plasmid to aid in the enrichment of recombinants after the initial 
recombination event. It is located outside of the area of recombination so that the final 
recombinant virus will not contain the gpt cassette after a second recombination event 
that selects against gpt. 
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Table 6-1. Primers used in β-lactamase-A4 plasmid pMC243 and pMC245 construction 
 
  
 
 
 
 
 
Primer 
Name Primer Nickname Primer Sequence Notes 
olMC192 Fwd A4 left flank 5’-CTCCGTTCTTTTCGAT GACTATAGGACAAGA-3’ 
 
olMC193 Rev A4 left flank 
5’-TTTCACCAGCGTTTCT 
GGGTCCATTTAAGGCTT
TAAAATTGAATTGCG-3’ 
Contains the 
beginning of the 
β-lactamase gene 
(initial codon 
underlined) 
olMC194 Fwd beta-lac 5’-GACCCAGAAACGCTG GTGAAAG-3’ 
 
olMC195 Rev beta-lac 5’-CCAATGCTTAATCAG TGAGGC-3’ 
 
olMC196 Fwd A4 right flank 
5’-GCCTCACTGATTAAG 
CATTGGGGCGGAGGCGA
CTTCTTTAACAAGTTCTC
ACAGGGG-3’ 
Contains the end 
of the β-lactamase 
gene and a three 
glycine linker 
(underlined) 
olMC197 Rev A4 right flank 
5’-CGTACTCCAATCATGT 
GTAGATGCTACTTCGTC
GATGG-3’ 
 
olMC199 Gpt FWD primer 
5’-AACTGCAGCAGCTGC 
ATATGTAAAAGTT-3’ 
Contains 5’ PstI 
restriction site 
(underlined) 
olMC200 Gpt REV primer 
5’-AACTGCAGGCGGCCG 
CGTCGACCCGGG-3’ 
Contains 5’ PstI 
restriction site 
(underlined) 
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 To increase the ability to isolate a recombinant virus with β-lactamase fused in 
frame to the A4L gene, we added the E. coli gpt selection cassette to pMC243. Gpt was 
amplified by PCR from the plasmid pel-P1-gpt using the primers olMC199 and 
olMC200. The gpt PCR product was then inserted into pMC243 to create the plasmid 
pMC245 (Fig. 6-1) and insertion of the gpt selectable marker was confirmed by 
sequencing.  
 
Detection of β-lactamase-A4 fusion protein expression and activity from plasmid 
pMC243. 
 Before creating a recombinant virus, we wished to confirm that the β-lactamase-
A4 fusion protein would be produced and stable inside infected cells. Therefore, we 
transfected RK-13 cells with pMC243 and subsequently infected them with VACV WR 
for 48 hours. Cells receiving only pMC243 or VACV WR were used as controls. To 
confirm expression of β-lactamase-A4 from pMC243, we performed western blots with 
cell lysates and probed using anti-A4 antibody at 1 µg/mL (R236, polyclonal rabbit anti-
VACV A4 peptide antibody generously provided by Gary Cohen and Roselyn 
Eisenberg). Cells that were transfected with pMC243 and infected with VACV WR for 
48 hours produced a recombinant β-lactamase-A4 fusion protein at a predicted MW of 
~60-70 kDa, while cells receiving either plasmid or virus alone did not (Fig. 6-2). This 
indicates that the recombinant protein was produced in cells and is not rapidly degraded. 
 To determine if the recombinant β-lactamase-A4 fusion protein had β-lactamase 
activity, we again transfected cells with pMC243 and infected them with VACV WR for 
24 or 48 hours. Cells receiving plasmid or virus only were used as negative controls.  
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Figure 6-2. Protein expression of β-lactamase-A4 fusion protein from pMC243 
transfected cells infected with VACV.  
RK-13 cells were transfected with pMC243 and infected with VACV WR (lane 
243/VACV). Control cells were either just infected with VACV WR (lane VACV) or just 
transfected pMC243 (lane 243). At 48 hours post infection, cells were harvested, pelleted, 
and lysed. Western blots were performed using cell lysate under denaturing/reducing 
conditions and probed using purified αA4 rabbit polyclonal antibody. Wild-type A4 was 
detected at 39 kDa in both of the VACV infected cell lysates, but not in cells only 
transfected with pMC243 as expression from the endogenous A4 promoter requires 
VACV infection. Transfected/infected cell lysate also contained a larger protein at the 
predicted size for the β-lactamase-A4 fusion protein (~60-70kDa: β-lactamase is 31.5 
kDa and A4 is 39 kDa). 
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Cells were lysed and cell lysate was mixed with nitrocefin (EMD Biosciences, La Jolla, 
CA), a yellow substrate that turns red after being hydrolyzed by β-lactamase. We found 
that cell lysates that were transfected with pMC243 and infected with VACV WR had β-
lactamase activity (Fig. 6-3). Therefore, the β-lactamase-A4 fusion protein retains β-
lactamase activity. 
 
Recombinant virus isolation. 
 A confluent T-25 flask of CV-1 cells were infected at an MOI of ~0.5 with 
VACV WR for 2 hours and then transfected with pMC245. After 48 hours, the cells were 
harvested, freeze/thawed three times, and sonicated. To isolate recombinant virus with 
the β-lactamase-A4 fusion protein, we used both positive and negative gpt selection. 
First, three rounds of plaque picking under positive drug selection was used to isolate a 
recombinant that had gpt inserted into its genome. This was done by growing virus in 
media containing mycophenolic acid, xanthine, and hypoxanthine (317) and picking 
plaques from wells where small numbers of plaques formed. After the third plaque pick, 
this virus was used to do two growths of virus under gpt positive selection to amplify the 
virus and obtain a larger pool of recombinant virus that contained the β-lactamase-A4 
fusion protein and gpt cassette. During these growths, the presence of the β-lactamase-A4 
fusion protein and gpt cassette in recombinant virus was confirmed using PCR and β-
lactamase activity was assayed using nitrocefin with cell lysates as before. Once we felt 
we had a pool of virus that was enriched with recombinant viruses, we used negative gpt 
selection to remove the gpt cassette while screening for plaques that retained β-lactamase 
activity. To do this, recombinant virus underwent two rounds of plaque purification in the 
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Figure 6-3. β-lactamase activity in pMC243 transfected and VACV infected cell 
lysates.  
BSC-1 cells were transfected with pMC243 and infected with VACV WR (243/VACV). 
Control cells were either transfected pMC243 (243) or infected with VACV WR 
(VACV). At 24 and 48 hours post infection (hpi), cells were harvested, pelleted, and 
lysed. Cell lysates were mixed 1:1 with yellow nitrocefin β-lactamase substrate (1 mM 
solution). Cell lysate from transfected/infected cells caused the nitrocefin to turn red 
indicating the presence of β-lactamase and that β-lactamase-A4 fusion protein retained β-
lactamase activity. Nitrocefin remained yellow in the presence of transfected or infected 
cell lysate indicating that β-lactamase was not present. 
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presence of 6-thioguanine, a drug that selects against the inserted gpt selection cassette 
when virus is plaqued on a hypoxanthine-guanine phosphoribosyltransferase-negative 
cell line of mouse fibroblasts (318). During this process, plaques were also screened 
using CCF2/AM live-cell β-lactamase substrate (Invitrogen) to identify and pick plaques 
that fluoresce blue indicating that β-lactamase-A4 was present. Once plaques were 
obtained that no longer contained the gpt selection cassette but continued to fluoresce 
blue in the presence of CCF2/AM, we performed an additional 7 rounds of plaque 
purification using CCF2/AM live-cell β-lactamase substrate to ensure no wild- type virus 
was present. The resulting plaque purified virus was added to BSC-1 cells in limiting 
dilutions so that a well on a 24-well plate only had 1 plaque on it. This plaque was 
allowed to grow until the entire well was infected (~6 days). The resulting recombinant 
virus was plaqued again and confirmed to only make plaques that fluoresced blue in the 
presence of CCF2/AM. Four of these plaques were picked and labeled A through D. The 
resulting plaque purified virus (vMC211A and vMC211C) underwent successive rounds 
of amplification by growth in increasing amounts of BSC-1 cells. A final large growth 
underwent virus purification by pelleting through a sucrose cushion. The presence of β-
lactamase-A4 fusion protein and absence of wild-type A4 protein and gpt cassette in the 
resulting recombinant virus stocks was confirmed by PCR and sequencing. Virus was 
confirmed to have β-lactamase activity using CCF2/AM live-cell β-lactamase substrate 
on infected cells and nitrocefin β-lactamase substrate on infected cell lysates. 
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Detection of β-lactamase-A4 fusion protein in purified recombinant virions. 
 To confirm incorporation of the β-lactamase-A4 fusion protein in virions, we 
performed western blots using purified virions. Blots were probed with the rabbit anti-A4 
antibody at 1 µg/mL. Indeed, β-lactamase-A4 fusion protein (~60-70kDA) was found in 
purified recombinant virions (Fig. 6-4), though we have yet to compare relative amounts 
of β-lactamase-A4 fusion protein to A4 found in wild type virions. 
 When growing vMC211, we observed smaller plaque sizes and slower growth 
than normally seen with wild-type virus (data not shown). Preliminary results of the 
optical density of purified recombinant and wild-type viruses may indicate that the 
recombinant virus has a higher particle to pfu ratio than wild type virus (data not shown). 
Because of the growth characteristics of the virus, the recombinant virions may be 
different than wild-type virions. Thus, there will be concern that its entry may be 
different than wild-type. However, this can be tested using the core penetration assay. 
The core penetration assay, along with electron microscopy, can also help confirm the 
difference in particle to pfu ratio between the recombinant and wild type viruses. 
Additionally, we will confirm that other proteins important for entry are incorporated 
normally into the recombinant virion. 
 In the future, experimental conditions for both rapid in-plate and FACS entry 
inhibition assays utilizing the live-cell CCF2/AM β-lactamase substrate can be pursued. 
These assays would be powerful tools to have to study poxvirus entry and to rapidly 
screen entry inhibitors. 
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Figure 6-4. β-lactamase-A4 fusion protein is incorporated into recombinant 
virions.  
Western blots were performed using purified recombinant β-lactamase-A4 expressing 
virions under reducing/denaturing conditions and probed using purified αA4 rabbit 
polyclonal antibody. 1 µL of purified virions was run on the gel along with a 1:10 
dilution. β-lactamase-A4 fusion protein was detected between 60-70kDa indicating that 
the recombinant protein was incorporated into virions. 
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